All questions marked with a red asterisk (*)
require a response. Questions without a red asterisk may or may not
require a response, depending on those questions' applicability to this
study.
1.1* Study Title:
Understanding Code Synthesis via Functional Magnetic Resonance Imaging
1.1.1 Full Study Title:
1.1.2 If there are other U-M studies related
to this project, enter the eResearch ID number (HUM#) or IRBMED Legacy
study number. Examples of related projects include, but are not
limited to:
Projects funded under the same grant
IRBMED Legacy study being migrated into eResearch
Previously approved Umbrella applications (such as Center Grants or approvals for release of funding)
Previously approved projects for which this is a follow up study
HUM00093760 – Routine Functional Magnetic Resonance Imaging of the Brain
1.2* Principal Investigator:
Westley Weimer Note: If the user is not in the system, you may Create A New User Account...
Code synthesis is the
creation of computer source code by a developer. Code synthesis occurs
as a software developer writes new source code to add or change
functionality of a computer program to add or change features or to fix
existing problems. Code synthesis is instrumental in the development
and maintenance of software. Software developers often
(unintentionally) introduce bugs and security vulnerabilities during
code synthesis, resulting in low quality software that requires
significant additional effort to correct via code review or software
maintenance. While many studies have addressed best practices for code
review and code style to reduce the likelihood of bugs or
vulnerabilities remaining in software, none have approached
understanding the cognitive processes involved in code synthesis. This
study proposes using functional magnetic resonance imaging (fMRI) to
measure those cognitive processes.
We believe that understanding
the correlation between code synthesis and related tasks will inform the
software engineering community about how to better assess or train
individuals who write software. This study will ask participants to
write code and perform similar baseline tasks in the fMRI machine to
measure these correlations.
In particular, there are two
baselines to which we intend to compare code synthesis. The first is
code review, or the systematic examination of computer source code.
Code review requires understanding snippets of code to assess whether it
contains bugs or vulnerabilities. Participants will be asked to
examine short snippets of code and choose whether the code is
acceptable.
Secondly, this study will compare code synthesis to
English prose writing. Participants will be shown a prompt and asked to
write a new sentence or passage in response. This is aimed to mimic
the writing aspect of code synthesis. Much like code synthesis involves
a developer writing new code to meet a desired behavior, this study
will ask participants to communicate ideas in writing in response to a
particular question or prompt.
In this study, participants
will answer questionnaires about their (1) socioeconomic status and
educational attainment, (2) Autism Spectrum Quotient, (3) score on the
Positive Affect / Negative Affect Scale (PANAS) and Need for Cognition
(NFS), and (4) spatial ability via a Paper Folding Test (PFT). Next,
they will complete a training session. Then, they will spent
approximately one hour in the fMRI rotating between code synthesis, code
review, and English prose writing. They will subsequently complete a
short post-questionnaire which will ask them to explain their answers to
the previous tasks. This post-questionnaire will be audio-recorded.
The
data generated will be used to find correlations between tasks and
survey data. We hypothesize that cognitive processes involved in code
synthesis will be similar to the prose writing tasks, though we expect
differences in the code review task. The similarities between these
tasks will help the software engineering community to improve training
for individuals involved in software development.
Amendment 85172:
We
added four more surveys to be collected from each participant
(socioeconomic status, Autism spectrum Quotient, PANAS/NFS, and PFT).
These will be collected before their scheduled imaging appointment.
Additionally,
we added audio-recording the post-questionnaire for more reliably
reporting qualitative aspects of the code and prose synthesis tasks. We
will transcribe the audio recordings for analysis as well.
1.10*Estimated Study Start Date (Not required for IRBMED): (mm/dd/yyyy)
3/1/2017
1.11*Estimated Duration of Study:
120 minutes per participant, multiple participants over the course of 12 weeks.
Approved
01-1. Application Type
1-1.1* Select the appropriate application type.
Standard, non-exempt, research project
Note: Please contact the IRB office before continuing with this application type.
Application Type
Description
Human Subjects research involving interaction or intervention(formerly Standard, non-exempt research project - or - Exempt)
Studies that involve either or both of the following:
Interaction, including communication or interpersonal contact between investigator and subject
Intervention, including both physical procedures by
which information or biospecimens are gathered (e.g., venipuncture) and
manipulations of the subject or subject’s environment that are performed
for research purposes
Interaction/Intervention studies may also have a "secondary research" component.
Does the research involve any of the following:
more than minimal risk to participants?
use of drugs or medical devices?
target prisoners as research subjects?
collection of biospecimens from subjects (including blood, saliva, cheek swabs)?
YesNo
Some
studies involving interaction or intervention with subjects meet the
criteria for exemption. Select the category that best describes your
research. Detailed questions to verify eligibility are found on the next
page. For some studies, you will be able to issue a self-determination.
If none of these categories apply to your research select
NONE. Your application will be routed for comprehensive IRB review.
Exemption Category
Secondary research uses of private information or biospecimens
"Secondary
research" are studies that involve ONLY re-using private information
and/or biospecimens that are collected for some other "primary" or
"initial" activity, such as other earlier research studies, a
biorepository holding specimens obtained with "broad consent," clinical
care, or educational records. Includes Exemption 4 and “not regulated”
projects.
Do NOT use this application type for:
Studies that also have an
interaction/intervention component, such as primary collection of
information or biospecimens for the purposes of the study. (Choose
instead "Human subjects research involving interaction or intervention.")
Projects involving secondary use of information/biospecimens for only non- research purposes,
such as QA/QI, case studies on one or two individuals, or use in a
class to teach research methods. (Choose instead "Activities not regulated as human subjects research.")
Activities Not Regulated as human subjects research
Not
all activities that involve people, their data, or specimens are
covered by the regulations governing human subjects research (45 CFR 46
or 21 CFR 50/56).
IRB review is required for the following activities ONLY to assess compliance with HIPAA or other regulations or institutional policies:
Research on existing data or specimens that have been coded before the researcher receives them, but identifiers still exist.
Research Involving Deceased Individuals Only
Pre-review of Clinical Data Sets Preparatory to Research
Standard Public Health Surveillance or Prevention Activities
IRB review is not required for the following activities,
but researchers may wish complete this brief application to generate a
determination letter for funding or publication purposes, or to request
IRB review to confirm the “Not Regulated” determination:
Case Studies
Class Activities
Journalism/Documentary Activities
Oral History
Quality Assurance and Quality Improvement Activities
Research on Organizations
Research using Publicly Available Data Sets
Projects lacking immediate plans for involvement of human subjects, their data, and/or their specimens
Activities
such as training grants, program projects, center grants, or
multi-phase studies not involving human subjects until later years.
Before release of funding, some agencies may require IRB acknowledgement
of the future use of human subjects.
These projects are sometimes referred to as "umbrella projects" or "dry applications."
Use
of an investigational drug or biologic, outside of a clinical trial,
under a single-patient IND issued by the FDA for a patient faced with a
serious or life-threatening disease or condition.
Contact the IRB Chair-on-Call as soon as possible once the decision to use the investigational drug or biologic is made.
Submission for IRB review and approval is required, prior to use if feasible. If this was an emergency use, submit no later than five days after use of the investigational agent.
This includes both one-time use and continuing therapy.
Use
of an investigational device, outside of a clinical trial, when this is
the only option available for a patient faced with a serious or
life-threatening disease or condition.
Contact the IRB Chair-on-Call as soon as possible once the decision to use the investigational device is made.
Submission for IRB review and approval is required, prior to device use if feasible. If this was an emergency use, submit no later than five days after use of the investigational device.
This includes both one-time use and continuing therapy.
Humanitarian Use Device (HUD) under a HDE
Non-research, on-label use of an HUD under a Humanitarian Device Exemption (HDE)
Requesting Review by a Non-UM IRB
Use ONLY to request deferral of IRB oversight for UM activities to a non-UM IRB.
Multi-site Research where U-M is a Coordinating Center and/or IRB of Record
Do not use Multi-site Research application type when U-M is only a performance site - select Standard application type.
Select when U-M is any of the following:
Data Coordinating Center;
Clinical Coordinating Center; or
IRB of Record for non-U-M sites (for U-M to be IRB of Record you must contact your IRB for prior acknowledgement).
When U-M is also a performance site, a separate application is required for local site considerations.
Refer to special requirements at the IRB website.
Note: Please contact the IRB office before continuing with this application type.
01-2. Standard Study Information
1-2.1* Who initiated this study?
Investigator
1-2.2* Are you or any students working on this project being paid from a federally funded training grant?
YesNo
1-2.3 This study is
currently associated with the following department. To associate
this research with a different department, click Select. If the
department has defaulted to "student", click select to specify the
department through which this application is being submitted.
CoE Electrical & Computer Sci
1-2.4 Will the study utilize resources from the following centers?
Select all that apply:
There are no items to display
1-2.5* Is the study related to cancer, cancer risk, or cancer care delivery?
YesNo
1-2.6* Does this study require review by the Rogel Cancer Center Protocol Review Committee (PRC)?
YesNo
1-2.7*
Has the scientific merit of this study already been peer reviewed
(i.e., reviewed by one or more recognized authorities on the
subject)?
YesNo
1-2.7.1* List the peer-review organization(s).
Peer Review Organization
There are no items to display
1-2.8* Is this a clinical trial?
YesNo
1-2.8.1* Please select the trial phase
Trial Phase
Description
If other, please specify:
1-2.9*
Would the integrity of this research study be compromised if the
subject were able to view results of their research tests or medications
in the Patient Portal of MyUofMHealth.org? Research results displayed
to the subject in MyUofMHealth.org will include: lab results, radiology
examinations and outpatient medication lists. Contracts and protocols
should be assessed by the Principal Investigator for specific language
regarding blinding of subjects and their research results.
1-2.10* Does the study involve administration of a cell therapy product?
YesNo
Please
download the Cellular Therapies Scientific Review Committee
Application, linked to in the help text, and upload the document with
your answers to section 44.1.
1.6 Allow this person to
EDIT the application, including any supporting documents/stipulations
requested during the review process:
Yes
1.7 Include this person on all correspondences regarding this application: (Note: This will include all committee correspondence, decision outcomes, renewal notices, and adverse event submissions.)
Credentials: Required for PI, Co-Is and Faculty Advisors
Upload or update your CV, resume, or biographical sketch.
Financial Interest Screening Questions for Study Team Members Not Affiliated with the University of Michigan: Required for all roles except Administrative Staff
Below, you be asked several questions intended to identify Financial Interests and relationships that may be relevant to THIS RESEARCH.
These may include Intellectual Property Interests (IP interests), as
well as relationships with entities whose interests may affect/be
affected by this research. If relevant to this research, you
should also consider companies that compete commercially with the
research sponsor or the manufacturer of the study drug, device or other
investigational item if you know that the competitor's Financial
Interests would reasonably appear to be affected by this research.
In relation to THIS RESEARCH, for the past
12 months, do you or your Family member (your spouse, domestic partner,
or dependent) have or anticipate having any of the following Financial
Interests:
F1. Are any activities or relationships
with an entity, whether paid or unpaid, where that entity's
financial interests could be affected by this research? Examples
include service on a board of directors, service on a scientific
advisory board, consultant, officer, manager, or partner.
F2. An Equity Interest
in any publicly traded or privately owned entity whose financial
interests could be affected by this research, including but not limited
to shares of stock or stock options? DO NOT include equity held in
a mutual, pension, or investment fund over which you have no control
with regard to investment decisions.
F3. An investorship or ownership interest in any Intellectual Property (IP)
that is being tested, evaluated, developed in, or its commercial value
will be affected by this research? This includes IP that is the
subject of a copyright, issued patent or a patent application
(regardless of whether it has been licensed or optioned).
F4. Any payments over
$5,000 (USD) received for the past 12 months (apart from any payments
from the University of Michigan), including salary, honoraria, fees, or
other forms of compensation or anything of value, from any entity that
has a financial interest in this research?
F5. If any of the above is answered "yes", you must complete this form and upload the completed form below.
Conflict of Interest Detail: Required for all roles except Administrative Staff
Current Disclosure Status in M-Inform:This study team member has indicated in M-inform that they do not have any outside interests to disclose.
Providing a product used in this project (e.g., an app, device, compound, drug, software, survey, evaluation);
Holding an option/license to intellectual property used in
this project (e.g., a device, compound, drug, software, survey,
evaluation) that you developed; or
Receiving a subcontract for work on this project?
*Examples of relevant interests or relationships with a
non-UM entity include owning stock in, receiving income from, consulting
with, serving as an officer/director/advisor to, or having some other
related financial/leadership interest or relationship with that entity.
No
D2 If “Yes” to the question above, provide the
name of the outside entity or entities and a brief description of the
interest/relationship(s):
C1 Do you, your spouse,
domestic partner, or dependents have any outside interests or
relationships to companies or entities related to this research that the
IRB should consider?
Examples of outside interests include, but are not limited to the following:
receiving compensation whose value could be affected by the study outcome
IN THE AGGREGATE, expecting to
receive compensation from the sponsor of the research of $10,000 or
greater in the next year
having a proprietary interest in the sponsor of the
research or a product tested by this research including but not limited
to, a patent, trademark, copyright, or licensing agreement, or the right
to receive royalties from product commercialization
individually or collectively, having an ownership interest
(equity or stock options) in the sponsor of the research or product
being tested whose value cannot be readily determined through reference
to public prices
individually or collectively, having an ownership interest
(equity or stock options) in a company or product whose value could be
affected by the study outcome
IN THE AGGREGATE, having an ownership interest (equity or
stock options) in the sponsor of the research that exceeds $10,000 or 1%
when the sponsor is a publicly traded entity
receiving significant payments of other sorts with an
aggregate value of $10,000 or more (or payment of ANY amount to medical
school or hospital employees) made directly by the sponsor of this
research for unrestricted research or education, equipment, consultancy,
or honorarium
holding a position of management or leadership in company
or entity related to this research including, but not limited to,
officer, director, or member of an advisory board.
providing consulting services or serve on a Speaker’s
Bureau, either paid or unpaid, to the financial or non-financial sponsor
of this study
when the sponsor is a publicly traded entity, having any ownership interest (equity or stock options) in the sponsor
expecting to receive any loans, educational support,
contributions of in-kind for equipment, or any other non-compensatory
payment from the sponsor of the research in the next year
C2 Please provide a detailed description of the outside interest in the box below.
C2.1 Where have you submitted a disclosure of this outside interest?
C2.2 Has a management plan been formalized?
C2.2.1 Click the View Management Plan in M-Inform button below to see your management plan for this study.
C2.2.2 If no, describe the
financial interest in sufficient detail to permit the COI Ancillary
Committee and the IRB to determine if such involvement represents a
potential conflict-of-interest and/or should be disclosed to potential
research subjects in the informed consent form.
1.6 Allow this person to
EDIT the application, including any supporting documents/stipulations
requested during the review process:
Yes
1.7 Include this person on all correspondences regarding this application: (Note: This will include all committee correspondence, decision outcomes, renewal notices, and adverse event submissions.)
Yes
Credentials: Required for PI, Co-Is and Faculty Advisors
Upload or update your CV, resume, or biographical sketch.
Financial Interest Screening Questions for Study Team Members Not Affiliated with the University of Michigan: Required for all roles except Administrative Staff
Below, you be asked several questions intended to identify Financial Interests and relationships that may be relevant to THIS RESEARCH.
These may include Intellectual Property Interests (IP interests), as
well as relationships with entities whose interests may affect/be
affected by this research. If relevant to this research, you
should also consider companies that compete commercially with the
research sponsor or the manufacturer of the study drug, device or other
investigational item if you know that the competitor's Financial
Interests would reasonably appear to be affected by this research.
In relation to THIS RESEARCH, for the past
12 months, do you or your Family member (your spouse, domestic partner,
or dependent) have or anticipate having any of the following Financial
Interests:
F1. Are any activities or relationships
with an entity, whether paid or unpaid, where that entity's
financial interests could be affected by this research? Examples
include service on a board of directors, service on a scientific
advisory board, consultant, officer, manager, or partner.
F2. An Equity Interest
in any publicly traded or privately owned entity whose financial
interests could be affected by this research, including but not limited
to shares of stock or stock options? DO NOT include equity held in
a mutual, pension, or investment fund over which you have no control
with regard to investment decisions.
F3. An investorship or ownership interest in any Intellectual Property (IP)
that is being tested, evaluated, developed in, or its commercial value
will be affected by this research? This includes IP that is the
subject of a copyright, issued patent or a patent application
(regardless of whether it has been licensed or optioned).
F4. Any payments over
$5,000 (USD) received for the past 12 months (apart from any payments
from the University of Michigan), including salary, honoraria, fees, or
other forms of compensation or anything of value, from any entity that
has a financial interest in this research?
F5. If any of the above is answered "yes", you must complete this form and upload the completed form below.
Conflict of Interest Detail: Required for all roles except Administrative Staff
Current Disclosure Status in M-Inform:This study team member has indicated in M-inform that they do not have any outside interests to disclose.
Providing a product used in this project (e.g., an app, device, compound, drug, software, survey, evaluation);
Holding an option/license to intellectual property used in
this project (e.g., a device, compound, drug, software, survey,
evaluation) that you developed; or
Receiving a subcontract for work on this project?
*Examples of relevant interests or relationships with a
non-UM entity include owning stock in, receiving income from, consulting
with, serving as an officer/director/advisor to, or having some other
related financial/leadership interest or relationship with that entity.
No
D2 If “Yes” to the question above, provide the
name of the outside entity or entities and a brief description of the
interest/relationship(s):
C1 Do you, your spouse,
domestic partner, or dependents have any outside interests or
relationships to companies or entities related to this research that the
IRB should consider?
Examples of outside interests include, but are not limited to the following:
receiving compensation whose value could be affected by the study outcome
IN THE AGGREGATE, expecting to
receive compensation from the sponsor of the research of $10,000 or
greater in the next year
having a proprietary interest in the sponsor of the
research or a product tested by this research including but not limited
to, a patent, trademark, copyright, or licensing agreement, or the right
to receive royalties from product commercialization
individually or collectively, having an ownership interest
(equity or stock options) in the sponsor of the research or product
being tested whose value cannot be readily determined through reference
to public prices
individually or collectively, having an ownership interest
(equity or stock options) in a company or product whose value could be
affected by the study outcome
IN THE AGGREGATE, having an ownership interest (equity or
stock options) in the sponsor of the research that exceeds $10,000 or 1%
when the sponsor is a publicly traded entity
receiving significant payments of other sorts with an
aggregate value of $10,000 or more (or payment of ANY amount to medical
school or hospital employees) made directly by the sponsor of this
research for unrestricted research or education, equipment, consultancy,
or honorarium
holding a position of management or leadership in company
or entity related to this research including, but not limited to,
officer, director, or member of an advisory board.
providing consulting services or serve on a Speaker’s
Bureau, either paid or unpaid, to the financial or non-financial sponsor
of this study
when the sponsor is a publicly traded entity, having any ownership interest (equity or stock options) in the sponsor
expecting to receive any loans, educational support,
contributions of in-kind for equipment, or any other non-compensatory
payment from the sponsor of the research in the next year
C2 Please provide a detailed description of the outside interest in the box below.
C2.1 Where have you submitted a disclosure of this outside interest?
C2.2 Has a management plan been formalized?
C2.2.1 Click the View Management Plan in M-Inform button below to see your management plan for this study.
C2.2.2 If no, describe the
financial interest in sufficient detail to permit the COI Ancillary
Committee and the IRB to determine if such involvement represents a
potential conflict-of-interest and/or should be disclosed to potential
research subjects in the informed consent form.
1.6 Allow this person to
EDIT the application, including any supporting documents/stipulations
requested during the review process:
Yes
1.7 Include this person on all correspondences regarding this application: (Note: This will include all committee correspondence, decision outcomes, renewal notices, and adverse event submissions.)
Yes
Credentials: Required for PI, Co-Is and Faculty Advisors
Upload or update your CV, resume, or biographical sketch.
Financial Interest Screening Questions for Study Team Members Not Affiliated with the University of Michigan: Required for all roles except Administrative Staff
Below, you be asked several questions intended to identify Financial Interests and relationships that may be relevant to THIS RESEARCH.
These may include Intellectual Property Interests (IP interests), as
well as relationships with entities whose interests may affect/be
affected by this research. If relevant to this research, you
should also consider companies that compete commercially with the
research sponsor or the manufacturer of the study drug, device or other
investigational item if you know that the competitor's Financial
Interests would reasonably appear to be affected by this research.
In relation to THIS RESEARCH, for the past
12 months, do you or your Family member (your spouse, domestic partner,
or dependent) have or anticipate having any of the following Financial
Interests:
F1. Are any activities or relationships
with an entity, whether paid or unpaid, where that entity's
financial interests could be affected by this research? Examples
include service on a board of directors, service on a scientific
advisory board, consultant, officer, manager, or partner.
F2. An Equity Interest
in any publicly traded or privately owned entity whose financial
interests could be affected by this research, including but not limited
to shares of stock or stock options? DO NOT include equity held in
a mutual, pension, or investment fund over which you have no control
with regard to investment decisions.
F3. An investorship or ownership interest in any Intellectual Property (IP)
that is being tested, evaluated, developed in, or its commercial value
will be affected by this research? This includes IP that is the
subject of a copyright, issued patent or a patent application
(regardless of whether it has been licensed or optioned).
F4. Any payments over
$5,000 (USD) received for the past 12 months (apart from any payments
from the University of Michigan), including salary, honoraria, fees, or
other forms of compensation or anything of value, from any entity that
has a financial interest in this research?
F5. If any of the above is answered "yes", you must complete this form and upload the completed form below.
Conflict of Interest Detail: Required for all roles except Administrative Staff
Current Disclosure Status in M-Inform:This study team member has not yet disclosed in M-Inform.
Providing a product used in this project (e.g., an app, device, compound, drug, software, survey, evaluation);
Holding an option/license to intellectual property used in
this project (e.g., a device, compound, drug, software, survey,
evaluation) that you developed; or
Receiving a subcontract for work on this project?
*Examples of relevant interests or relationships with a
non-UM entity include owning stock in, receiving income from, consulting
with, serving as an officer/director/advisor to, or having some other
related financial/leadership interest or relationship with that entity.
No
D2 If “Yes” to the question above, provide the
name of the outside entity or entities and a brief description of the
interest/relationship(s):
C1 Do you, your spouse,
domestic partner, or dependents have any outside interests or
relationships to companies or entities related to this research that the
IRB should consider?
Examples of outside interests include, but are not limited to the following:
receiving compensation whose value could be affected by the study outcome
IN THE AGGREGATE, expecting to
receive compensation from the sponsor of the research of $10,000 or
greater in the next year
having a proprietary interest in the sponsor of the
research or a product tested by this research including but not limited
to, a patent, trademark, copyright, or licensing agreement, or the right
to receive royalties from product commercialization
individually or collectively, having an ownership interest
(equity or stock options) in the sponsor of the research or product
being tested whose value cannot be readily determined through reference
to public prices
individually or collectively, having an ownership interest
(equity or stock options) in a company or product whose value could be
affected by the study outcome
IN THE AGGREGATE, having an ownership interest (equity or
stock options) in the sponsor of the research that exceeds $10,000 or 1%
when the sponsor is a publicly traded entity
receiving significant payments of other sorts with an
aggregate value of $10,000 or more (or payment of ANY amount to medical
school or hospital employees) made directly by the sponsor of this
research for unrestricted research or education, equipment, consultancy,
or honorarium
holding a position of management or leadership in company
or entity related to this research including, but not limited to,
officer, director, or member of an advisory board.
providing consulting services or serve on a Speaker’s
Bureau, either paid or unpaid, to the financial or non-financial sponsor
of this study
when the sponsor is a publicly traded entity, having any ownership interest (equity or stock options) in the sponsor
expecting to receive any loans, educational support,
contributions of in-kind for equipment, or any other non-compensatory
payment from the sponsor of the research in the next year
C2 Please provide a detailed description of the outside interest in the box below.
C2.1 Where have you submitted a disclosure of this outside interest?
C2.2 Has a management plan been formalized?
C2.2.1 Click the View Management Plan in M-Inform button below to see your management plan for this study.
C2.2.2 If no, describe the
financial interest in sufficient detail to permit the COI Ancillary
Committee and the IRB to determine if such involvement represents a
potential conflict-of-interest and/or should be disclosed to potential
research subjects in the informed consent form.
1.6 Allow this person to
EDIT the application, including any supporting documents/stipulations
requested during the review process:
Yes
1.7 Include this person on all correspondences regarding this application: (Note: This will include all committee correspondence, decision outcomes, renewal notices, and adverse event submissions.)
Yes
Credentials: Required for PI, Co-Is and Faculty Advisors
Upload or update your CV, resume, or biographical sketch.
Financial Interest Screening Questions for Study Team Members Not Affiliated with the University of Michigan: Required for all roles except Administrative Staff
Below, you be asked several questions intended to identify Financial Interests and relationships that may be relevant to THIS RESEARCH.
These may include Intellectual Property Interests (IP interests), as
well as relationships with entities whose interests may affect/be
affected by this research. If relevant to this research, you
should also consider companies that compete commercially with the
research sponsor or the manufacturer of the study drug, device or other
investigational item if you know that the competitor's Financial
Interests would reasonably appear to be affected by this research.
In relation to THIS RESEARCH, for the past
12 months, do you or your Family member (your spouse, domestic partner,
or dependent) have or anticipate having any of the following Financial
Interests:
F1. Are any activities or relationships
with an entity, whether paid or unpaid, where that entity's
financial interests could be affected by this research? Examples
include service on a board of directors, service on a scientific
advisory board, consultant, officer, manager, or partner.
F2. An Equity Interest
in any publicly traded or privately owned entity whose financial
interests could be affected by this research, including but not limited
to shares of stock or stock options? DO NOT include equity held in
a mutual, pension, or investment fund over which you have no control
with regard to investment decisions.
F3. An investorship or ownership interest in any Intellectual Property (IP)
that is being tested, evaluated, developed in, or its commercial value
will be affected by this research? This includes IP that is the
subject of a copyright, issued patent or a patent application
(regardless of whether it has been licensed or optioned).
F4. Any payments over
$5,000 (USD) received for the past 12 months (apart from any payments
from the University of Michigan), including salary, honoraria, fees, or
other forms of compensation or anything of value, from any entity that
has a financial interest in this research?
F5. If any of the above is answered "yes", you must complete this form and upload the completed form below.
Conflict of Interest Detail: Required for all roles except Administrative Staff
Current Disclosure Status in M-Inform:This study team member has not yet disclosed in M-Inform.
Providing a product used in this project (e.g., an app, device, compound, drug, software, survey, evaluation);
Holding an option/license to intellectual property used in
this project (e.g., a device, compound, drug, software, survey,
evaluation) that you developed; or
Receiving a subcontract for work on this project?
*Examples of relevant interests or relationships with a
non-UM entity include owning stock in, receiving income from, consulting
with, serving as an officer/director/advisor to, or having some other
related financial/leadership interest or relationship with that entity.
No
D2 If “Yes” to the question above, provide the
name of the outside entity or entities and a brief description of the
interest/relationship(s):
C1 Do you, your spouse,
domestic partner, or dependents have any outside interests or
relationships to companies or entities related to this research that the
IRB should consider?
Examples of outside interests include, but are not limited to the following:
receiving compensation whose value could be affected by the study outcome
IN THE AGGREGATE, expecting to
receive compensation from the sponsor of the research of $10,000 or
greater in the next year
having a proprietary interest in the sponsor of the
research or a product tested by this research including but not limited
to, a patent, trademark, copyright, or licensing agreement, or the right
to receive royalties from product commercialization
individually or collectively, having an ownership interest
(equity or stock options) in the sponsor of the research or product
being tested whose value cannot be readily determined through reference
to public prices
individually or collectively, having an ownership interest
(equity or stock options) in a company or product whose value could be
affected by the study outcome
IN THE AGGREGATE, having an ownership interest (equity or
stock options) in the sponsor of the research that exceeds $10,000 or 1%
when the sponsor is a publicly traded entity
receiving significant payments of other sorts with an
aggregate value of $10,000 or more (or payment of ANY amount to medical
school or hospital employees) made directly by the sponsor of this
research for unrestricted research or education, equipment, consultancy,
or honorarium
holding a position of management or leadership in company
or entity related to this research including, but not limited to,
officer, director, or member of an advisory board.
providing consulting services or serve on a Speaker’s
Bureau, either paid or unpaid, to the financial or non-financial sponsor
of this study
when the sponsor is a publicly traded entity, having any ownership interest (equity or stock options) in the sponsor
expecting to receive any loans, educational support,
contributions of in-kind for equipment, or any other non-compensatory
payment from the sponsor of the research in the next year
C2 Please provide a detailed description of the outside interest in the box below.
C2.1 Where have you submitted a disclosure of this outside interest?
C2.2 Has a management plan been formalized?
C2.2.1 Click the View Management Plan in M-Inform button below to see your management plan for this study.
C2.2.2 If no, describe the
financial interest in sufficient detail to permit the COI Ancillary
Committee and the IRB to determine if such involvement represents a
potential conflict-of-interest and/or should be disclosed to potential
research subjects in the informed consent form.
1.6 Allow this person to
EDIT the application, including any supporting documents/stipulations
requested during the review process:
Yes
1.7 Include this person on all correspondences regarding this application: (Note: This will include all committee correspondence, decision outcomes, renewal notices, and adverse event submissions.)
Yes
Credentials: Required for PI, Co-Is and Faculty Advisors
Upload or update your CV, resume, or biographical sketch.
Financial Interest Screening Questions for Study Team Members Not Affiliated with the University of Michigan: Required for all roles except Administrative Staff
Below, you be asked several questions intended to identify Financial Interests and relationships that may be relevant to THIS RESEARCH.
These may include Intellectual Property Interests (IP interests), as
well as relationships with entities whose interests may affect/be
affected by this research. If relevant to this research, you
should also consider companies that compete commercially with the
research sponsor or the manufacturer of the study drug, device or other
investigational item if you know that the competitor's Financial
Interests would reasonably appear to be affected by this research.
In relation to THIS RESEARCH, for the past
12 months, do you or your Family member (your spouse, domestic partner,
or dependent) have or anticipate having any of the following Financial
Interests:
F1. Are any activities or relationships
with an entity, whether paid or unpaid, where that entity's
financial interests could be affected by this research? Examples
include service on a board of directors, service on a scientific
advisory board, consultant, officer, manager, or partner.
F2. An Equity Interest
in any publicly traded or privately owned entity whose financial
interests could be affected by this research, including but not limited
to shares of stock or stock options? DO NOT include equity held in
a mutual, pension, or investment fund over which you have no control
with regard to investment decisions.
F3. An investorship or ownership interest in any Intellectual Property (IP)
that is being tested, evaluated, developed in, or its commercial value
will be affected by this research? This includes IP that is the
subject of a copyright, issued patent or a patent application
(regardless of whether it has been licensed or optioned).
F4. Any payments over
$5,000 (USD) received for the past 12 months (apart from any payments
from the University of Michigan), including salary, honoraria, fees, or
other forms of compensation or anything of value, from any entity that
has a financial interest in this research?
F5. If any of the above is answered "yes", you must complete this form and upload the completed form below.
Conflict of Interest Detail: Required for all roles except Administrative Staff
Current Disclosure Status in M-Inform:This study team member has not yet disclosed in M-Inform.
Providing a product used in this project (e.g., an app, device, compound, drug, software, survey, evaluation);
Holding an option/license to intellectual property used in
this project (e.g., a device, compound, drug, software, survey,
evaluation) that you developed; or
Receiving a subcontract for work on this project?
*Examples of relevant interests or relationships with a
non-UM entity include owning stock in, receiving income from, consulting
with, serving as an officer/director/advisor to, or having some other
related financial/leadership interest or relationship with that entity.
No
D2 If “Yes” to the question above, provide the
name of the outside entity or entities and a brief description of the
interest/relationship(s):
C1 Do you, your spouse,
domestic partner, or dependents have any outside interests or
relationships to companies or entities related to this research that the
IRB should consider?
Examples of outside interests include, but are not limited to the following:
receiving compensation whose value could be affected by the study outcome
IN THE AGGREGATE, expecting to
receive compensation from the sponsor of the research of $10,000 or
greater in the next year
having a proprietary interest in the sponsor of the
research or a product tested by this research including but not limited
to, a patent, trademark, copyright, or licensing agreement, or the right
to receive royalties from product commercialization
individually or collectively, having an ownership interest
(equity or stock options) in the sponsor of the research or product
being tested whose value cannot be readily determined through reference
to public prices
individually or collectively, having an ownership interest
(equity or stock options) in a company or product whose value could be
affected by the study outcome
IN THE AGGREGATE, having an ownership interest (equity or
stock options) in the sponsor of the research that exceeds $10,000 or 1%
when the sponsor is a publicly traded entity
receiving significant payments of other sorts with an
aggregate value of $10,000 or more (or payment of ANY amount to medical
school or hospital employees) made directly by the sponsor of this
research for unrestricted research or education, equipment, consultancy,
or honorarium
holding a position of management or leadership in company
or entity related to this research including, but not limited to,
officer, director, or member of an advisory board.
providing consulting services or serve on a Speaker’s
Bureau, either paid or unpaid, to the financial or non-financial sponsor
of this study
when the sponsor is a publicly traded entity, having any ownership interest (equity or stock options) in the sponsor
expecting to receive any loans, educational support,
contributions of in-kind for equipment, or any other non-compensatory
payment from the sponsor of the research in the next year
C2 Please provide a detailed description of the outside interest in the box below.
C2.1 Where have you submitted a disclosure of this outside interest?
C2.2 Has a management plan been formalized?
C2.2.1 Click the View Management Plan in M-Inform button below to see your management plan for this study.
C2.2.2 If no, describe the
financial interest in sufficient detail to permit the COI Ancillary
Committee and the IRB to determine if such involvement represents a
potential conflict-of-interest and/or should be disclosed to potential
research subjects in the informed consent form.
1.6 Allow this person to
EDIT the application, including any supporting documents/stipulations
requested during the review process:
Yes
1.7 Include this person on all correspondences regarding this application: (Note: This will include all committee correspondence, decision outcomes, renewal notices, and adverse event submissions.)
Yes
Credentials: Required for PI, Co-Is and Faculty Advisors
Upload or update your CV, resume, or biographical sketch.
Financial Interest Screening Questions for Study Team Members Not Affiliated with the University of Michigan: Required for all roles except Administrative Staff
Below, you be asked several questions intended to identify Financial Interests and relationships that may be relevant to THIS RESEARCH.
These may include Intellectual Property Interests (IP interests), as
well as relationships with entities whose interests may affect/be
affected by this research. If relevant to this research, you
should also consider companies that compete commercially with the
research sponsor or the manufacturer of the study drug, device or other
investigational item if you know that the competitor's Financial
Interests would reasonably appear to be affected by this research.
In relation to THIS RESEARCH, for the past
12 months, do you or your Family member (your spouse, domestic partner,
or dependent) have or anticipate having any of the following Financial
Interests:
F1. Are any activities or relationships
with an entity, whether paid or unpaid, where that entity's
financial interests could be affected by this research? Examples
include service on a board of directors, service on a scientific
advisory board, consultant, officer, manager, or partner.
F2. An Equity Interest
in any publicly traded or privately owned entity whose financial
interests could be affected by this research, including but not limited
to shares of stock or stock options? DO NOT include equity held in
a mutual, pension, or investment fund over which you have no control
with regard to investment decisions.
F3. An investorship or ownership interest in any Intellectual Property (IP)
that is being tested, evaluated, developed in, or its commercial value
will be affected by this research? This includes IP that is the
subject of a copyright, issued patent or a patent application
(regardless of whether it has been licensed or optioned).
F4. Any payments over
$5,000 (USD) received for the past 12 months (apart from any payments
from the University of Michigan), including salary, honoraria, fees, or
other forms of compensation or anything of value, from any entity that
has a financial interest in this research?
F5. If any of the above is answered "yes", you must complete this form and upload the completed form below.
Conflict of Interest Detail: Required for all roles except Administrative Staff
Current Disclosure Status in M-Inform:This study team member has not yet disclosed in M-Inform.
Providing a product used in this project (e.g., an app, device, compound, drug, software, survey, evaluation);
Holding an option/license to intellectual property used in
this project (e.g., a device, compound, drug, software, survey,
evaluation) that you developed; or
Receiving a subcontract for work on this project?
*Examples of relevant interests or relationships with a
non-UM entity include owning stock in, receiving income from, consulting
with, serving as an officer/director/advisor to, or having some other
related financial/leadership interest or relationship with that entity.
No
D2 If “Yes” to the question above, provide the
name of the outside entity or entities and a brief description of the
interest/relationship(s):
C1 Do you, your spouse,
domestic partner, or dependents have any outside interests or
relationships to companies or entities related to this research that the
IRB should consider?
Examples of outside interests include, but are not limited to the following:
receiving compensation whose value could be affected by the study outcome
IN THE AGGREGATE, expecting to
receive compensation from the sponsor of the research of $10,000 or
greater in the next year
having a proprietary interest in the sponsor of the
research or a product tested by this research including but not limited
to, a patent, trademark, copyright, or licensing agreement, or the right
to receive royalties from product commercialization
individually or collectively, having an ownership interest
(equity or stock options) in the sponsor of the research or product
being tested whose value cannot be readily determined through reference
to public prices
individually or collectively, having an ownership interest
(equity or stock options) in a company or product whose value could be
affected by the study outcome
IN THE AGGREGATE, having an ownership interest (equity or
stock options) in the sponsor of the research that exceeds $10,000 or 1%
when the sponsor is a publicly traded entity
receiving significant payments of other sorts with an
aggregate value of $10,000 or more (or payment of ANY amount to medical
school or hospital employees) made directly by the sponsor of this
research for unrestricted research or education, equipment, consultancy,
or honorarium
holding a position of management or leadership in company
or entity related to this research including, but not limited to,
officer, director, or member of an advisory board.
providing consulting services or serve on a Speaker’s
Bureau, either paid or unpaid, to the financial or non-financial sponsor
of this study
when the sponsor is a publicly traded entity, having any ownership interest (equity or stock options) in the sponsor
expecting to receive any loans, educational support,
contributions of in-kind for equipment, or any other non-compensatory
payment from the sponsor of the research in the next year
C2 Please provide a detailed description of the outside interest in the box below.
C2.1 Where have you submitted a disclosure of this outside interest?
C2.2 Has a management plan been formalized?
C2.2.1 Click the View Management Plan in M-Inform button below to see your management plan for this study.
C2.2.2 If no, describe the
financial interest in sufficient detail to permit the COI Ancillary
Committee and the IRB to determine if such involvement represents a
potential conflict-of-interest and/or should be disclosed to potential
research subjects in the informed consent form.
1.6 Allow this person to
EDIT the application, including any supporting documents/stipulations
requested during the review process:
No
1.7 Include this person on all correspondences regarding this application: (Note: This will include all committee correspondence, decision outcomes, renewal notices, and adverse event submissions.)
No
Credentials: Required for PI, Co-Is and Faculty Advisors
Upload or update your CV, resume, or biographical sketch.
Financial Interest Screening Questions for Study Team Members Not Affiliated with the University of Michigan: Required for all roles except Administrative Staff
Below, you be asked several questions intended to identify Financial Interests and relationships that may be relevant to THIS RESEARCH.
These may include Intellectual Property Interests (IP interests), as
well as relationships with entities whose interests may affect/be
affected by this research. If relevant to this research, you
should also consider companies that compete commercially with the
research sponsor or the manufacturer of the study drug, device or other
investigational item if you know that the competitor's Financial
Interests would reasonably appear to be affected by this research.
In relation to THIS RESEARCH, for the past
12 months, do you or your Family member (your spouse, domestic partner,
or dependent) have or anticipate having any of the following Financial
Interests:
F1. Are any activities or relationships
with an entity, whether paid or unpaid, where that entity's
financial interests could be affected by this research? Examples
include service on a board of directors, service on a scientific
advisory board, consultant, officer, manager, or partner.
F2. An Equity Interest
in any publicly traded or privately owned entity whose financial
interests could be affected by this research, including but not limited
to shares of stock or stock options? DO NOT include equity held in
a mutual, pension, or investment fund over which you have no control
with regard to investment decisions.
F3. An investorship or ownership interest in any Intellectual Property (IP)
that is being tested, evaluated, developed in, or its commercial value
will be affected by this research? This includes IP that is the
subject of a copyright, issued patent or a patent application
(regardless of whether it has been licensed or optioned).
F4. Any payments over
$5,000 (USD) received for the past 12 months (apart from any payments
from the University of Michigan), including salary, honoraria, fees, or
other forms of compensation or anything of value, from any entity that
has a financial interest in this research?
F5. If any of the above is answered "yes", you must complete this form and upload the completed form below.
Conflict of Interest Detail: Required for all roles except Administrative Staff
Current Disclosure Status in M-Inform:This study team member has not yet disclosed in M-Inform.
Providing a product used in this project (e.g., an app, device, compound, drug, software, survey, evaluation);
Holding an option/license to intellectual property used in
this project (e.g., a device, compound, drug, software, survey,
evaluation) that you developed; or
Receiving a subcontract for work on this project?
*Examples of relevant interests or relationships with a
non-UM entity include owning stock in, receiving income from, consulting
with, serving as an officer/director/advisor to, or having some other
related financial/leadership interest or relationship with that entity.
No
D2 If “Yes” to the question above, provide the
name of the outside entity or entities and a brief description of the
interest/relationship(s):
C1 Do you, your spouse,
domestic partner, or dependents have any outside interests or
relationships to companies or entities related to this research that the
IRB should consider?
Examples of outside interests include, but are not limited to the following:
receiving compensation whose value could be affected by the study outcome
IN THE AGGREGATE, expecting to
receive compensation from the sponsor of the research of $10,000 or
greater in the next year
having a proprietary interest in the sponsor of the
research or a product tested by this research including but not limited
to, a patent, trademark, copyright, or licensing agreement, or the right
to receive royalties from product commercialization
individually or collectively, having an ownership interest
(equity or stock options) in the sponsor of the research or product
being tested whose value cannot be readily determined through reference
to public prices
individually or collectively, having an ownership interest
(equity or stock options) in a company or product whose value could be
affected by the study outcome
IN THE AGGREGATE, having an ownership interest (equity or
stock options) in the sponsor of the research that exceeds $10,000 or 1%
when the sponsor is a publicly traded entity
receiving significant payments of other sorts with an
aggregate value of $10,000 or more (or payment of ANY amount to medical
school or hospital employees) made directly by the sponsor of this
research for unrestricted research or education, equipment, consultancy,
or honorarium
holding a position of management or leadership in company
or entity related to this research including, but not limited to,
officer, director, or member of an advisory board.
providing consulting services or serve on a Speaker’s
Bureau, either paid or unpaid, to the financial or non-financial sponsor
of this study
when the sponsor is a publicly traded entity, having any ownership interest (equity or stock options) in the sponsor
expecting to receive any loans, educational support,
contributions of in-kind for equipment, or any other non-compensatory
payment from the sponsor of the research in the next year
C2 Please provide a detailed description of the outside interest in the box below.
C2.1 Where have you submitted a disclosure of this outside interest?
C2.2 Has a management plan been formalized?
C2.2.1 Click the View Management Plan in M-Inform button below to see your management plan for this study.
C2.2.2 If no, describe the
financial interest in sufficient detail to permit the COI Ancillary
Committee and the IRB to determine if such involvement represents a
potential conflict-of-interest and/or should be disclosed to potential
research subjects in the informed consent form.
1.6 Allow this person to
EDIT the application, including any supporting documents/stipulations
requested during the review process:
Yes
1.7 Include this person on all correspondences regarding this application: (Note: This will include all committee correspondence, decision outcomes, renewal notices, and adverse event submissions.)
No
Credentials: Required for PI, Co-Is and Faculty Advisors
Upload or update your CV, resume, or biographical sketch.
Financial Interest Screening Questions for Study Team Members Not Affiliated with the University of Michigan: Required for all roles except Administrative Staff
Below, you be asked several questions intended to identify Financial Interests and relationships that may be relevant to THIS RESEARCH.
These may include Intellectual Property Interests (IP interests), as
well as relationships with entities whose interests may affect/be
affected by this research. If relevant to this research, you
should also consider companies that compete commercially with the
research sponsor or the manufacturer of the study drug, device or other
investigational item if you know that the competitor's Financial
Interests would reasonably appear to be affected by this research.
In relation to THIS RESEARCH, for the past
12 months, do you or your Family member (your spouse, domestic partner,
or dependent) have or anticipate having any of the following Financial
Interests:
F1. Are any activities or relationships
with an entity, whether paid or unpaid, where that entity's
financial interests could be affected by this research? Examples
include service on a board of directors, service on a scientific
advisory board, consultant, officer, manager, or partner.
No
F2. An Equity Interest
in any publicly traded or privately owned entity whose financial
interests could be affected by this research, including but not limited
to shares of stock or stock options? DO NOT include equity held in
a mutual, pension, or investment fund over which you have no control
with regard to investment decisions.
No
F3. An investorship or ownership interest in any Intellectual Property (IP)
that is being tested, evaluated, developed in, or its commercial value
will be affected by this research? This includes IP that is the
subject of a copyright, issued patent or a patent application
(regardless of whether it has been licensed or optioned).
No
F4. Any payments over
$5,000 (USD) received for the past 12 months (apart from any payments
from the University of Michigan), including salary, honoraria, fees, or
other forms of compensation or anything of value, from any entity that
has a financial interest in this research?
No
F5. If any of the above is answered "yes", you must complete this form and upload the completed form below.
Conflict of Interest Detail: Required for all roles except Administrative Staff
Current Disclosure Status in M-Inform:This study team member has not yet disclosed in M-Inform.
Providing a product used in this project (e.g., an app, device, compound, drug, software, survey, evaluation);
Holding an option/license to intellectual property used in
this project (e.g., a device, compound, drug, software, survey,
evaluation) that you developed; or
Receiving a subcontract for work on this project?
*Examples of relevant interests or relationships with a
non-UM entity include owning stock in, receiving income from, consulting
with, serving as an officer/director/advisor to, or having some other
related financial/leadership interest or relationship with that entity.
D2 If “Yes” to the question above, provide the
name of the outside entity or entities and a brief description of the
interest/relationship(s):
C1 Do you, your spouse,
domestic partner, or dependents have any outside interests or
relationships to companies or entities related to this research that the
IRB should consider?
Examples of outside interests include, but are not limited to the following:
receiving compensation whose value could be affected by the study outcome
IN THE AGGREGATE, expecting to
receive compensation from the sponsor of the research of $10,000 or
greater in the next year
having a proprietary interest in the sponsor of the
research or a product tested by this research including but not limited
to, a patent, trademark, copyright, or licensing agreement, or the right
to receive royalties from product commercialization
individually or collectively, having an ownership interest
(equity or stock options) in the sponsor of the research or product
being tested whose value cannot be readily determined through reference
to public prices
individually or collectively, having an ownership interest
(equity or stock options) in a company or product whose value could be
affected by the study outcome
IN THE AGGREGATE, having an ownership interest (equity or
stock options) in the sponsor of the research that exceeds $10,000 or 1%
when the sponsor is a publicly traded entity
receiving significant payments of other sorts with an
aggregate value of $10,000 or more (or payment of ANY amount to medical
school or hospital employees) made directly by the sponsor of this
research for unrestricted research or education, equipment, consultancy,
or honorarium
holding a position of management or leadership in company
or entity related to this research including, but not limited to,
officer, director, or member of an advisory board.
providing consulting services or serve on a Speaker’s
Bureau, either paid or unpaid, to the financial or non-financial sponsor
of this study
when the sponsor is a publicly traded entity, having any ownership interest (equity or stock options) in the sponsor
expecting to receive any loans, educational support,
contributions of in-kind for equipment, or any other non-compensatory
payment from the sponsor of the research in the next year
No
C2 Please provide a detailed description of the outside interest in the box below.
C2.1 Where have you submitted a disclosure of this outside interest?
C2.2 Has a management plan been formalized?
C2.2.1 Click the View Management Plan in M-Inform button below to see your management plan for this study.
C2.2.2 If no, describe the
financial interest in sufficient detail to permit the COI Ancillary
Committee and the IRB to determine if such involvement represents a
potential conflict-of-interest and/or should be disclosed to potential
research subjects in the informed consent form.
1.6 Allow this person to
EDIT the application, including any supporting documents/stipulations
requested during the review process:
Yes
1.7 Include this person on all correspondences regarding this application: (Note: This will include all committee correspondence, decision outcomes, renewal notices, and adverse event submissions.)
No
Credentials: Required for PI, Co-Is and Faculty Advisors
Upload or update your CV, resume, or biographical sketch.
Financial Interest Screening Questions for Study Team Members Not Affiliated with the University of Michigan: Required for all roles except Administrative Staff
Below, you be asked several questions intended to identify Financial Interests and relationships that may be relevant to THIS RESEARCH.
These may include Intellectual Property Interests (IP interests), as
well as relationships with entities whose interests may affect/be
affected by this research. If relevant to this research, you
should also consider companies that compete commercially with the
research sponsor or the manufacturer of the study drug, device or other
investigational item if you know that the competitor's Financial
Interests would reasonably appear to be affected by this research.
In relation to THIS RESEARCH, for the past
12 months, do you or your Family member (your spouse, domestic partner,
or dependent) have or anticipate having any of the following Financial
Interests:
F1. Are any activities or relationships
with an entity, whether paid or unpaid, where that entity's
financial interests could be affected by this research? Examples
include service on a board of directors, service on a scientific
advisory board, consultant, officer, manager, or partner.
No
F2. An Equity Interest
in any publicly traded or privately owned entity whose financial
interests could be affected by this research, including but not limited
to shares of stock or stock options? DO NOT include equity held in
a mutual, pension, or investment fund over which you have no control
with regard to investment decisions.
No
F3. An investorship or ownership interest in any Intellectual Property (IP)
that is being tested, evaluated, developed in, or its commercial value
will be affected by this research? This includes IP that is the
subject of a copyright, issued patent or a patent application
(regardless of whether it has been licensed or optioned).
No
F4. Any payments over
$5,000 (USD) received for the past 12 months (apart from any payments
from the University of Michigan), including salary, honoraria, fees, or
other forms of compensation or anything of value, from any entity that
has a financial interest in this research?
No
F5. If any of the above is answered "yes", you must complete this form and upload the completed form below.
Conflict of Interest Detail: Required for all roles except Administrative Staff
Current Disclosure Status in M-Inform:This study team member has not yet disclosed in M-Inform.
Providing a product used in this project (e.g., an app, device, compound, drug, software, survey, evaluation);
Holding an option/license to intellectual property used in
this project (e.g., a device, compound, drug, software, survey,
evaluation) that you developed; or
Receiving a subcontract for work on this project?
*Examples of relevant interests or relationships with a
non-UM entity include owning stock in, receiving income from, consulting
with, serving as an officer/director/advisor to, or having some other
related financial/leadership interest or relationship with that entity.
D2 If “Yes” to the question above, provide the
name of the outside entity or entities and a brief description of the
interest/relationship(s):
C1 Do you, your spouse,
domestic partner, or dependents have any outside interests or
relationships to companies or entities related to this research that the
IRB should consider?
Examples of outside interests include, but are not limited to the following:
receiving compensation whose value could be affected by the study outcome
IN THE AGGREGATE, expecting to
receive compensation from the sponsor of the research of $10,000 or
greater in the next year
having a proprietary interest in the sponsor of the
research or a product tested by this research including but not limited
to, a patent, trademark, copyright, or licensing agreement, or the right
to receive royalties from product commercialization
individually or collectively, having an ownership interest
(equity or stock options) in the sponsor of the research or product
being tested whose value cannot be readily determined through reference
to public prices
individually or collectively, having an ownership interest
(equity or stock options) in a company or product whose value could be
affected by the study outcome
IN THE AGGREGATE, having an ownership interest (equity or
stock options) in the sponsor of the research that exceeds $10,000 or 1%
when the sponsor is a publicly traded entity
receiving significant payments of other sorts with an
aggregate value of $10,000 or more (or payment of ANY amount to medical
school or hospital employees) made directly by the sponsor of this
research for unrestricted research or education, equipment, consultancy,
or honorarium
holding a position of management or leadership in company
or entity related to this research including, but not limited to,
officer, director, or member of an advisory board.
providing consulting services or serve on a Speaker’s
Bureau, either paid or unpaid, to the financial or non-financial sponsor
of this study
when the sponsor is a publicly traded entity, having any ownership interest (equity or stock options) in the sponsor
expecting to receive any loans, educational support,
contributions of in-kind for equipment, or any other non-compensatory
payment from the sponsor of the research in the next year
No
C2 Please provide a detailed description of the outside interest in the box below.
C2.1 Where have you submitted a disclosure of this outside interest?
C2.2 Has a management plan been formalized?
C2.2.1 Click the View Management Plan in M-Inform button below to see your management plan for this study.
C2.2.2 If no, describe the
financial interest in sufficient detail to permit the COI Ancillary
Committee and the IRB to determine if such involvement represents a
potential conflict-of-interest and/or should be disclosed to potential
research subjects in the informed consent form.
02. Sponsor/Support Information
The following sections request details
about the current or pending sponsorship/support of this study. Consider
all of the choices below and complete the appropriate sections.
* Note: At
least one of the following sections must be answered. Multiple forms of
funding or support must be added one at a time.
2.1 Please select all
Proposal Approval Forms (PAFs), Awards (AWDs), and/or Unfunded
Agreements (UFAs) associated with this study.
Click here to indicate that a PAF(s) has not been initiated.
ID
Title
PI
Direct Sponsor
Prime Sponsor
State
Has SUBKs?
Related Awards
There are no items to display
Award ID
Title
PI
Direct Sponsor
Prime Sponsor
State
Has SUBKs?
Project Period
Awarded PAFs
There are no items to display
UFA ID
Title
PI
State
Category
Start Date
End Date
There are no items to display
Note: As of 6/10/2018, details
of the External Sponsor/Support have been replaced by linking to
submissions in the eResearch Proposal Management system.
3.1* Indicate all functions that will be performed at University of Michigan locations.
Select all that apply:
Recruitment (including screening)
Interaction (e.g., information gathering, survey, interview, focus groups, etc.)
Intervention
(e.g., use of drug or device, medical procedures, educational
intervention, group intervention, social/psychological intervention
etc.)
Observation of behavior (direct or indirect)
Qualitative research (e.g., 'member checking', open-ended questions, etc.)
Primary or secondary analysis (data/specimen)
Storage (data and/or specimen): Responsible for the management, security and transfer of study data and/or specimens.
If other, please specify.
If University of Michigan will be performing coordinating center activities, contact your IRB prior to continuing to ensure you have chosen the appropriate application type for your project.
3.1.1*
As the Operations, Coordinating or Lead Center describe the mechanisms
in place to ensure that management, data analysis, and Data Safety and
Monitoring systems are adequate for each site.
3.1.2* Describe the plan for communicating interim results (e.g. adverse events, unanticipated events or interim data):
3.1.3* Describe the plan for communicating any protocol modification by the site(s):
3.2* Will U-M be the IRB of Record?
An IRB is considered the IRB of Record when it assumes IRB responsibilities for another institution.
3-1.6 If known, provide the Federalwide Assurance (FWA) number for this location.
3-1.7 If applicable, indicate what
organization, agency or government office has reviewed this research and
provided its approval (e.g., IRB, ethics committee, school district
office, prison official, nursing home administrator).
IRB approval forthcoming based upon review here at UMich since we are leading the effort.
3-1.8 Upload any location site approval documentation here:
Name
Version
There are no items to display
Performance Site Detail
3-1.2* Location or Institution:
University of Michigan
3-1.3 Address:
City
State
Country*
USA
3-1.4* Function of this location with respect to this study:
Select all that apply:
Recruitment (including screening)
Interaction (e.g., information gathering, survey, interview, focus groups, etc.)
Intervention
(e.g., use of drug or device, medical procedures, educational
intervention, group intervention, social/psychological intervention
etc.)
Observation of behavior (direct or indirect)
Qualitative research (e.g., 'member checking', open-ended questions, etc.)
Primary or secondary analysis (data/specimen)
Storage (data and/or specimen): Responsible for the management, security and transfer of study data and/or specimens.
If other, please specify:
3-1.5* Will this site be "engaged" in the conduct of the research?
3-1.6 If known, provide the Federalwide Assurance (FWA) number for this location.
FWA00004969
3-1.7 If applicable, indicate what
organization, agency or government office has reviewed this research and
provided its approval (e.g., IRB, ethics committee, school district
office, prison official, nursing home administrator).
3-1.8 Upload any location site approval documentation here:
Name
Version
There are no items to display
05. Research Design
5.1* Is there a stand-alone scientific protocol document and/or research plan associated with this application?
YesNo
5.1.1* Click ADD to attach the document(s) electronically.
Name
Version
There are no items to display
5.1.2* Indicate the section where each of the following are covered in the attached protocol:
Objective
We
seek to investigate the neural representation of computer programming
in humans and relate it to English writing tasks. Results for this
study can inform future research about efficient computing pedagogy and
software engineering workforce training.
Specific Aim/Hypothesis
Based
on previous research concerning English reading and program
comprehension, we hypothesize that similar areas of the brain are
engaged when writing code and writing prose.
Background Information
The
process of designing software, commonly called Software Engineering,
involves many stages. While there are several differing models for this
process, most of them contain the same core phases: requirements
specification, software design, implementation, verification, and
maintenance. Briefly, requirements specifications describes the process
of deciding how to software is supposed to behave. Then, based upon
these requirements, a number of design decisions are made for the
software system in the software design stage. Implementation describes
the time actually coding the software system. In the verification stage,
software is tested to ensure that it adheres to its specifications.
After the software is sufficiently tested, it is deployed for use.
Finally, the maintenance stage describes the ongoing process of
repairing the software when a defect is found and supporting the users
of the software.
While each of these stages takes some time, it
has been shown that software maintenance is by far the most time
intensive phase of software development. This stems from a number of
reasons, but primarily from the fact that it is much more difficult to
repair a defect after the development stage. This could be true because
the software engineers are less familiar with the code as time goes by,
or because making a change to repair a defect can affect other parts of
the software that were built on top of the defect. Regardless of cause,
it has been empirically shown that the majority of software costs come
from this maintenance process. As a result, software companies are eager
to deploy any solution that will decrease the time spent in
maintenance.
One approach toward this goal is to make fewer
mistakes in the initial implementation process. Common practice to
address accomplish this includes adopting code review. Code review is
the systematic inspection, analysis, evaluation, and revision of code.
Among standard software engineering companies it is commonly
implemented in the following manner: when an engineer has finished
working on code that (s)he would like to submit to the main code base of
the project, (s)he submits a pull request which essentially asks a
coworker to review the code and, upon acceptance, incorporate it into
the main code base. If, however, the reviewer does not accept the pull
request, (s)he suggests changes that need to be made to the code before
it should be accepted. This practice ensures that both the original
coder and another engineer believe that the code is correct before it is
incorporated into the main code base. This practice has been shown to
drastically reduce the number of defects that reach the main code base
of the project. In industry, the process of code review is very commonly
used. For example, a software engineer at Facebook cannot submit a code
change until at least two coworkers have reviewed and accepted it.
While Facebook is a very stringent example, many companies practice some
version of this system.
So, while it has been shown that code
review is beneficial to companies because it decreases overall costs, it
is not understood exactly what is occurring in the brain during the
code rewriting activity. This study aims to uncover that information and
learn if this information can improve the ways we train or evaluate
engineers’ code writing skills. For instance, it has been proposed that
reading code is very similar to natural language processing. Believing
this to be true, it is natural to consider alternative training
techniques for software engineers that involve reading and perhaps
writing forms of language other than code.
To our knowledge,
only two previous studies have considered looking at the cognitive
processes involved in coding. Understanding understanding source code
with functional magnetic imaging was published in the International
Conference on Software Engineering in 2014. In this study, the cognitive
processes involved in the act of code comprehension - reading and
understanding code - are measured in an fMRI. The results of this
experiment support the aforementioned claim: reading code is very
similar to reading any other natural language. While this study
intrigued many researchers in the software engineering community, it did
not carry any opportunity for impacting the practices of the field. The
other study, Decoding the representation of code in the brain: An fMRI
study of code review and expertise, was published in ICSE in 2017 and
received a distinguished paper award. This study investigated the
neural activity involved in code comprehension and prose review,
ultimately finding a distinction between the two tasks. Our study aims
to apply many of the same techniques, but learn about a process that is
used very commonly in the software engineering field. It is our hope
that the results will be both intriguing and impactful to real software
companies.
Methodology
The fMRI portion of this study will be conducted in accordance with the blanket fMRI Master Protocol (HUM00093760).
We
will recruit participants from the undergraduate EECS student
population. First, we will use mailing lists to email undergraduate CS
majors about the study, benefits, risks, compensation, and skill level
required. We will also recruit in an undergraduate software engineering
course via a 2-3 minute presentation about joining the study. We will
wait for participants to contact us via email before scheduling a time
to come in.
Amendment 85172: We will email four survey
instruments to consenting participants to collect socioeconomic status,
their autism spectrum quotient, their PANAS/NFS scores, and their
performance on a paper-folding test. The paragraph below was updated to
reflect this addition as well.
After recruitment, we will email
the participant the informed consent documents as well as an explanation
about informed consent and the study. If they provide their consent,
we will subsequently email them four survey instruments to collect
socioeconomic and psychological data about the subject. We will
schedule a 90-minute session with each participant at the fMRI
laboratory. When they arrive, we will sit with them and remind them of
the informed consent procedure and the voluntary nature of the study.
If they reaffirm their consent, we will give them the background
questionnaire to assess their competency with C programming. This
questionnaire will take roughly 5-10 minutes and will be completed with a
pen and paper. Participants must answer every question correctly to
move on. If they do not pass, they will be instructed to leave and be
compensated $25. If they pass, they will be required to pass an MRI
safety screening. If they do not pass the safety screening, they will
be instructed to leave and be compensated $25. Next, they will be shown
a short training video about the fMRI study, including example tasks
and how they should interact with the study materials. The video will
last roughly 10 minutes. After answering any remaining questions, the
participant will enter the fMRI and the study will begin. During the
study, participants will be given 4 minutes to practice using an fMRI
safe keyboard for typing code while in the MRI tube. After this 4
minute block, we will ask them to complete a series of tasks, each 30
seconds long. For the first ~16 minutes, they will be shown code
writing tasks. They will be asked to complete a short snippet of code
to meet some objective (e.g., assign the variable a certain value).
Next, they will be shown a prompt and asked to write new code. Each
prompt will be 30 seconds and last a total of ~16 minutes. For the next
~16 minutes, they will be shown prose writing tasks. They will be
asked to respond to a prompt (e.g., how do you get dressed in the
morning?). For the final ~16 minutes, they will be asked a series of
prose editing questions. They will be shown a paragraph of text and a
candidate change, and asked whether the change improves the text or not.
There will be a 5 second break between each 30 second task, as well as
a 2 minute break between each 16 minute block.
After
completing the fMRI study, we will ask the participant three additional
questions about a response they gave in each block of tasks (i.e., code
writing, prose writing, and prose editing). We will record their
answers electronically (i.e., in an audio file). Afterwards, the
participant is free to leave. The participant will receive $75
compensation for their time.
Amendment 85172:
We will
audio-record the participant's post-questionnaire. The
post-questionnaire will not ask for any personally identifiable
information (although the recording itself is identifying). Within 30
days of the participant's appointment, Leach, Huang, or Krueger will
transcribe the audio to plain text stored on an encrypted volume, and
then dispose of the original audio files. The paragraph above reflects
this change.
We will develop example code writing tasks based upon mid-level undergraduate CS curriculum. They
will consist generally of code snippets with missing or mistaken parts
that require the participant to write a short piece of code within a 30
second window.
We will acquire prose writing samples based upon
standardized tests, including the SAT and ACT. They will generally
consist of tasks requiring the participant to write new words or
sentences within a 30 second time window.
We will apply
techniques from graph theory and statistical machine learning (e.g.,
GLM) to model spatial dependencies across brain regions and use those to
predict (i.e., decode) individual difference factors.
We will
apply established techniques for anonymizing the fMRI data by using
nifti_tool on the resulting NIFTI data produced by the MRI machine.
nifti_tool is a software package from the NIH that allows editing the
data produced by the MRI to provide anonymity.
https://afni.nimh.nih.gov/pub/dist/doc/program_help/nifti_tool.html.
We
plan to retain the anonymized fMRI and exit survey for use in future
studies, either for a baseline comparison or as part of a larger scale
review study of this and subsequent medical imaging studies we conduct.
We
will not collect personally identifiable information except for the
audio recording of the post questionnaire. The email address, name, and
mailing address of each participant will be used to scheduling time in
the MRI and as part of compensating them through HSIP. However, these
are separate from the study proper and will not be retained as part of
the research data. After the participant has finished, we will delete
previous electronic correspondence. We will retain the subject's email
address for 30 days after completion of their scan to notify them of any
incidental findings made during their scan.
An MRI technician
will conduct the scan on the subject. If the technician makes an
incidental finding during the scan of the subject, PI Weimer or Research
Fellow Leach will follow up with the subject via email (originally
acquired during scheduling). We will communicate the technician's
findings to the subject, and suggest that they follow up with a
physician to properly asses the incidental finding.
Statistical Design
1)
We intend to collect basic demographic information from participants so
that we can determine if differences in age, gender, sex, programming
language, and levels of experience affect the neural activations
associated with these tasks; and
2) We will employ techniques
from graph theory and statistical machine learning (e.g., GLM) to model
spatial dependencies across brain regions and use those to predict (i.e.
decode) individual difference factors.
AME00090429:
3) We
will employ novel statistical techniques to attempt improving insights
gained from this data. For instance, we will employ GIMME analyses and
other statistical techniques to distinguish between when subjects were
writing code vs. writing prose. Additionally, we will employ techniques
to understand brain activity for longer blocks of time--our study used
60 second blocks for some stimuli, while existing techniques generally
function well for 30 second blocks or shorter.
5.1.3* Study team Experience: Briefly outline the experience and competence of the study team to pursue the proposed study.
PI
Weimer has previously conducted IRB-approved fMRI research involving
software engineering while at the University of Virginia. Research
Fellow Kevin Leach and graduate student Yu Huang have both conducted
IRB-approved human studies. Co-investigator Santander has previously
collaborated with PI Weimer on IRB-approved fMRI human study
experiments. All four have published peer-reviewed publications based
upon such human studies. Co-investigator Xiaosu Hu and Jessica Kim have
experience on medical imaging human studies.
PI Weimer has extensive experience researching program analysis and software engineering.
PI
Weimer will be engaged in managing and funding the project, as well as
preparing manuscripts for publication. Research Fellow Leach and
Graduate Student Huang will both be engaged in recruiting participants,
preparing stimuli, conducting each human study trial, analyzing data,
and preparing manuscripts for publication. Co-investigator Santander
will be responsible for analyzing fMRI-specific data. Co-investigator
Xiaosu Hu and Jessica Kim will help with the data analysis.
AME00086288: Co-Investigator
Zohreh Sharafi has experience running IRB human studies related to
eye-tracking. In this study, Sharafi will help run subjects through the
protocol and collect and analyze research data.
AME00090429: Co-Investigator
Nicholas McKay is an undergraduate researcher who will be applying new
analyses to existing research data. He will not be interacting with
participants, and will be working only with de-identified research data
to gain new insights from our existing data.
5.2* Will the involvement of ANY subjects in this study be limited to analysis of their existing data or specimens?
YesNo
5.2.1* How many subjects are represented in the data or specimens to be analyzed?
(do not enter commas, dots, or special characters)
5.3* Will the study involve recruitment and/or participation of subjects in order to produce new data (e.g., surveys, interaction, intervention)? [Require sections 8-1 and 11-3]
YesNo
5.4* List the inclusion and exclusion criteria for this study population and/or data set. (If covered in attached protocol, indicate section)
Adults
aged 18-65 who meet the age requirements for undergoing MRI (e.g., no
pregnant women or former metalworkers) as well as expertise in CS. No
particular subgroups will be excluded.
In particular, the fMRI master protocol excludes the following:
- Individuals under 18 - pregnancy - claustrophobia - uncontrollable shaking - can’t lie still for one hour -
metallic or electronic implants in the body (pacemakers or pacemaker
wires, open heart surgery, artificial heart valve, brain aneurysm
surgery, middle ear implant, hearing aid, braces or extensive dental
work, cataract surgery or lens implant, implanted mechanical or
electrical device, or artificial limb or joint - foreign metallic objects in the body (bullets, BBs, pellets, schrapnel, or metalwork fragments) - current or past employment as machinists, welders or metal workers
5.5 Identify any racial,
ethnic, or gender group(s) that will be specifically excluded from
participation in this research study and provide a compelling
justification for such exclusion:
5.6* Indicate the age range (in years) of the subject population in this study.
Minimum Age:
18
Maximum Age:
65If no upper limit, enter "999"
5.7*
Will the study be conducted according to ICH-GCP E6 guidelines? Check
the study protocol (especially Signature Page and Ethical Guidelines
section) prior to answering this question. If the answer is “yes” – see
helptext for details.
YesNo
5.8*
The primary risk of conducting research with secondary data or
specimens is a breach of confidentiality or privacy, which may cause
psychological, social/reputation, legal, or financial harm. Indicate any
risks to subjects other than these risks from a breach of
confidentiality or privacy. If there are none, answer “none.”
In
its review of research applications, the IRB considers whether research
procedures are consistent with sound research design in order to yield
the expected results. Scientific merit is examined in relationship
to the risks and benefits of the research. This
section covers the overall research design of the project. Later
sections will ask more specific questions about benefits, risks, special
review considerations, targeted populations, recruitment strategies,
and experimental methodologies/procedures.
5-1.1* Objective: What is the overall purpose of this research study?
We
seek to investigate the neural representation of computer programming
in humans and relate it to English writing tasks. Results for this
study can inform future research about efficient computing pedagogy and
software engineering workforce training.
5-1.2*
Specific Aim(s): What is (are) the specific aim(s) of this study and/or
what hypothesis (hypotheses) is (are) to be tested?
Based
on previous research concerning English reading and program
comprehension, we hypothesize that similar areas of the brain are
engaged when writing code and writing prose.
5-1.3* Background: What prior information or knowledge exists to support the conduct of this study?
The
process of designing software, commonly called Software Engineering,
involves many stages. While there are several differing models for this
process, most of them contain the same core phases: requirements
specification, software design, implementation, verification, and
maintenance. Briefly, requirements specifications describes the process
of deciding how to software is supposed to behave. Then, based upon
these requirements, a number of design decisions are made for the
software system in the software design stage. Implementation describes
the time actually coding the software system. In the verification stage,
software is tested to ensure that it adheres to its specifications.
After the software is sufficiently tested, it is deployed for use.
Finally, the maintenance stage describes the ongoing process of
repairing the software when a defect is found and supporting the users
of the software.
While each of these stages takes some time, it
has been shown that software maintenance is by far the most time
intensive phase of software development. This stems from a number of
reasons, but primarily from the fact that it is much more difficult to
repair a defect after the development stage. This could be true because
the software engineers are less familiar with the code as time goes by,
or because making a change to repair a defect can affect other parts of
the software that were built on top of the defect. Regardless of cause,
it has been empirically shown that the majority of software costs come
from this maintenance process. As a result, software companies are eager
to deploy any solution that will decrease the time spent in
maintenance.
One approach toward this goal is to make fewer
mistakes in the initial implementation process. Common practice to
address accomplish this includes adopting code review. Code review is
the systematic inspection, analysis, evaluation, and revision of code.
Among standard software engineering companies it is commonly
implemented in the following manner: when an engineer has finished
working on code that (s)he would like to submit to the main code base of
the project, (s)he submits a pull request which essentially asks a
coworker to review the code and, upon acceptance, incorporate it into
the main code base. If, however, the reviewer does not accept the pull
request, (s)he suggests changes that need to be made to the code before
it should be accepted. This practice ensures that both the original
coder and another engineer believe that the code is correct before it is
incorporated into the main code base. This practice has been shown to
drastically reduce the number of defects that reach the main code base
of the project. In industry, the process of code review is very commonly
used. For example, a software engineer at Facebook cannot submit a code
change until at least two coworkers have reviewed and accepted it.
While Facebook is a very stringent example, many companies practice some
version of this system.
So, while it has been shown that code
review is beneficial to companies because it decreases overall costs, it
is not understood exactly what is occurring in the brain during the
code rewriting activity. This study aims to uncover that information and
learn if this information can improve the ways we train or evaluate
engineers’ code writing skills. For instance, it has been proposed that
reading code is very similar to natural language processing. Believing
this to be true, it is natural to consider alternative training
techniques for software engineers that involve reading and perhaps
writing forms of language other than code.
To our knowledge,
only two previous studies have considered looking at the cognitive
processes involved in coding. Understanding understanding source code
with functional magnetic imaging was published in the International
Conference on Software Engineering in 2014. In this study, the cognitive
processes involved in the act of code comprehension - reading and
understanding code - are measured in an fMRI. The results of this
experiment support the aforementioned claim: reading code is very
similar to reading any other natural language. While this study
intrigued many researchers in the software engineering community, it did
not carry any opportunity for impacting the practices of the field. The
other study, Decoding the representation of code in the brain: An fMRI
study of code review and expertise, was published in ICSE in 2017 and
received a distinguished paper award. This study investigated the
neural activity involved in code comprehension and prose review,
ultimately finding a distinction between the two tasks. Our study aims
to apply many of the same techniques, but learn about a process that is
used very commonly in the software engineering field. It is our hope
that the results will be both intriguing and impactful to real software
companies.
5-1.4*Briefly
outline the special expertise and qualifications of the PI,
Co-Investigators, and/or Faculty Advisors to conduct and/or oversee the
particular procedures or activities involved in this particularstudy. This will supplement information provided in the study team CVs.
PI
Weimer has previously conducted IRB-approved fMRI research involving
software engineering while at the University of Virginia. Research
Fellow Kevin Leach and graduate student Yu Huang have both conducted
IRB-approved human studies. Co-investigator Santander has previously
collaborated with PI Weimer on IRB-approved fMRI human study
experiments. All four have published peer-reviewed publications based
upon such human studies. Co-investigator Xiaosu Hu and Jessica Kim have
experience on medical imaging human studies.
PI Weimer has extensive experience researching program analysis and software engineering.
PI
Weimer will be engaged in managing and funding the project, as well as
preparing manuscripts for publication. Research Fellow Leach and
Graduate Student Huang will both be engaged in recruiting participants,
preparing stimuli, conducting each human study trial, analyzing data,
and preparing manuscripts for publication. Co-investigator Santander
will be responsible for analyzing fMRI-specific data. Co-investigator
Xiaosu Hu and Jessica Kim will help with the data analysis.
AME00086288: Co-Investigator
Zohreh Sharafi has experience running IRB human studies related to
eye-tracking. In this study, Sharafi will help run subjects through the
protocol and collect and analyze research data.
AME00090429: Co-Investigator
Nicholas McKay is an undergraduate researcher who will be applying new
analyses to existing research data. He will not be interacting with
participants, and will be working only with de-identified research data
to gain new insights from our existing data.
5-1.5*
Methodology: Describe the design and procedures to be used to
accomplish the specific aims of the study. Describe the advantages of
any innovative methodologies.
The fMRI portion of this study will be conducted in accordance with the blanket fMRI Master Protocol (HUM00093760).
We
will recruit participants from the undergraduate EECS student
population. First, we will use mailing lists to email undergraduate CS
majors about the study, benefits, risks, compensation, and skill level
required. We will also recruit in an undergraduate software engineering
course via a 2-3 minute presentation about joining the study. We will
wait for participants to contact us via email before scheduling a time
to come in.
Amendment 85172: We will email four survey
instruments to consenting participants to collect socioeconomic status,
their autism spectrum quotient, their PANAS/NFS scores, and their
performance on a paper-folding test. The paragraph below was updated to
reflect this addition as well.
After recruitment, we will email
the participant the informed consent documents as well as an explanation
about informed consent and the study. If they provide their consent,
we will subsequently email them four survey instruments to collect
socioeconomic and psychological data about the subject. We will
schedule a 90-minute session with each participant at the fMRI
laboratory. When they arrive, we will sit with them and remind them of
the informed consent procedure and the voluntary nature of the study.
If they reaffirm their consent, we will give them the background
questionnaire to assess their competency with C programming. This
questionnaire will take roughly 5-10 minutes and will be completed with a
pen and paper. Participants must answer every question correctly to
move on. If they do not pass, they will be instructed to leave and be
compensated $25. If they pass, they will be required to pass an MRI
safety screening. If they do not pass the safety screening, they will
be instructed to leave and be compensated $25. Next, they will be shown
a short training video about the fMRI study, including example tasks
and how they should interact with the study materials. The video will
last roughly 10 minutes. After answering any remaining questions, the
participant will enter the fMRI and the study will begin. During the
study, participants will be given 4 minutes to practice using an fMRI
safe keyboard for typing code while in the MRI tube. After this 4
minute block, we will ask them to complete a series of tasks, each 30
seconds long. For the first ~16 minutes, they will be shown code
writing tasks. They will be asked to complete a short snippet of code
to meet some objective (e.g., assign the variable a certain value).
Next, they will be shown a prompt and asked to write new code. Each
prompt will be 30 seconds and last a total of ~16 minutes. For the next
~16 minutes, they will be shown prose writing tasks. They will be
asked to respond to a prompt (e.g., how do you get dressed in the
morning?). For the final ~16 minutes, they will be asked a series of
prose editing questions. They will be shown a paragraph of text and a
candidate change, and asked whether the change improves the text or not.
There will be a 5 second break between each 30 second task, as well as
a 2 minute break between each 16 minute block.
After
completing the fMRI study, we will ask the participant three additional
questions about a response they gave in each block of tasks (i.e., code
writing, prose writing, and prose editing). We will record their
answers electronically (i.e., in an audio file). Afterwards, the
participant is free to leave. The participant will receive $75
compensation for their time.
Amendment 85172:
We will
audio-record the participant's post-questionnaire. The
post-questionnaire will not ask for any personally identifiable
information (although the recording itself is identifying). Within 30
days of the participant's appointment, Leach, Huang, or Krueger will
transcribe the audio to plain text stored on an encrypted volume, and
then dispose of the original audio files. The paragraph above reflects
this change.
We will develop example code writing tasks based upon mid-level undergraduate CS curriculum. They
will consist generally of code snippets with missing or mistaken parts
that require the participant to write a short piece of code within a 30
second window.
We will acquire prose writing samples based upon
standardized tests, including the SAT and ACT. They will generally
consist of tasks requiring the participant to write new words or
sentences within a 30 second time window.
We will apply
techniques from graph theory and statistical machine learning (e.g.,
GLM) to model spatial dependencies across brain regions and use those to
predict (i.e., decode) individual difference factors.
We will
apply established techniques for anonymizing the fMRI data by using
nifti_tool on the resulting NIFTI data produced by the MRI machine.
nifti_tool is a software package from the NIH that allows editing the
data produced by the MRI to provide anonymity.
https://afni.nimh.nih.gov/pub/dist/doc/program_help/nifti_tool.html.
We
plan to retain the anonymized fMRI and exit survey for use in future
studies, either for a baseline comparison or as part of a larger scale
review study of this and subsequent medical imaging studies we conduct.
We
will not collect personally identifiable information except for the
audio recording of the post questionnaire. The email address, name, and
mailing address of each participant will be used to scheduling time in
the MRI and as part of compensating them through HSIP. However, these
are separate from the study proper and will not be retained as part of
the research data. After the participant has finished, we will delete
previous electronic correspondence. We will retain the subject's email
address for 30 days after completion of their scan to notify them of any
incidental findings made during their scan.
An MRI technician
will conduct the scan on the subject. If the technician makes an
incidental finding during the scan of the subject, PI Weimer or Research
Fellow Leach will follow up with the subject via email (originally
acquired during scheduling). We will communicate the technician's
findings to the subject, and suggest that they follow up with a
physician to properly asses the incidental finding.
5-1.6* Statistical Design: Describe the statistical design of the research study, including methods used to analyze data.
1)
We intend to collect basic demographic information from participants so
that we can determine if differences in age, gender, sex, programming
language, and levels of experience affect the neural activations
associated with these tasks; and
2) We will employ techniques
from graph theory and statistical machine learning (e.g., GLM) to model
spatial dependencies across brain regions and use those to predict (i.e.
decode) individual difference factors.
AME00090429:
3) We
will employ novel statistical techniques to attempt improving insights
gained from this data. For instance, we will employ GIMME analyses and
other statistical techniques to distinguish between when subjects were
writing code vs. writing prose. Additionally, we will employ techniques
to understand brain activity for longer blocks of time--our study used
60 second blocks for some stimuli, while existing techniques generally
function well for 30 second blocks or shorter.
06. Benefits and Risks
6.1 * Describe the potential benefits of this research to society.
There
are no direct health benefits to the participants. The primary benefits
of the study are best realized at the societal and scientific levels.
The data gained from this study, along with the conclusions drawn from
it, will help shape and improve the software engineering workforce’s
code synthesis and review skills through improvements in training.
6.2 * Will results of the research be communicated back to the subjects?
YesNo
6.2.1 * Explain the plan and process.
6.3 * Describe any direct risks to the public or community, which could result from this research?
There are no direct risks to society at large.
6.4 *Does this project involve study arms that have differing levels of benefit or risks to subjects?
YesNo
6.5 * Benefits and Risks:
Click "Add" to begin entering the benefit and risk level detail information associated with this study.
If a study involves multiple arms or phases that pose
different levels of risk or direct benefits to subjects, then create an
entry for each arm or phase using the "OK and Add Another" option at the
bottom of this page. Only one entry is necessary if the risk
level and the direct benefit to subjects is the same for the entire
project, even if the study involves multiple arms or phases.
6.5.1 * Name of Arm (experimental group, study wave, etc.)
HUM00138634
6.5.2 * Description of Arm (experimental group, study wave, etc.)
6.6 * Are there potential direct benefits of this research to the subjects?
YesNo
6.6.1 * Describe the potential direct benefits.
6.7 *
Provide a description of the foreseeable risks to subjects. For
studies involving multiple arms or phases, enter the risks for this arm
or phase only.
Provide a description of the foreseeable risks to the subjects.
For EACH identified risk, include:
Likelihood of the risk,
Seriousness to the subject; and
What measures will be taken to minimize the risk
(for example, study design includes the substitution of procedures
already being performed on the subject for diagnostic or treatment
purposes, or in a study of Post-Traumatic Stress Disorder, the
investigator takes steps to identify, manage, or refer as appropriate,
subjects for whom the study may evoke very difficult emotions)
If
possible, please use the following categories to assess the likelihood:
"Common" (i.e., approximate incidence > 25%)
"Likely" (i.e., approximate incidence of 10-25%)
"Infrequent" (i.e., approximate incidence of 1-10%)
"Rare" (i.e., approximate incidence < 1%):
Risks associated with
fMRI are outlined in the Master Protocol and described in the informed
consent document. Risks associated with the routine fMRI protocol will
always be no more than minimal.
We collect fMRI data and audio
recordings of the post questionnaire, all of which are stored on an
encrypted volume. As with any networked enterprise, there is a risk
that a data breach will occur, which may result in compromising the
collected data. To minimize this risk, we will store research data on
an encrypted volume on a server kept in a locked office. The research
data will be anonymized, so that it cannot be used to learn the identity
of individual participants, even if the data is decrypted.
6.8 *
What is the level of risk of harm to the subjects, resulting from this
arm of the research? For studies involving multiple arms or
phases, enter the level of risk for this arm or phase only.
Risk Level
Description
6.9 * Discuss why the risks to the subjects are reasonable in relation to the anticipated benefits.
Potential risks in this
study include claustrophobia and discomfort in the MRI scanning
environment. Moreover, subjects will be given a demonstration of the
speed with which they can be removed from the MRI scanner if they feel
they need to quit the experiment in the middle of an experiment. Note:
The procedures used in this MRI study do not use any contrast agents.
There
are no direct health benefits to the participants. The primary benefits
of the study are best realized at the societal and scientific levels.
The data gained from this study, along with the conclusions drawn from
it, will help shape and improve the software engineering workforce’s
code synthesis and review skills through improvements in training.
Great
care is taken to minimize the risks inherent in the MRI environment
such that risk of physical injury is extremely unlikely, and risk of
significant psychological discomfort is likewise minimal. The
risk-benefit ratio is therefore acceptable.
07. Special Considerations
7.1* Does this study involve human tissue or biological specimens (use, collection, or secondary analysis) (e.g. blood, urine, bone marrow, skin, etc.)? [Require Section 18]
YesNo
7.1.1* Will genetic analysis be performed on any specimens acquired in conjunction with this study? [Require Section 20]
YesNo
7.2* Does this study involve the secondary analysis of a pre-existing data set, including data associated with any specimens identified in response to question 7.1? [Require Section 24]
YesNo
7.3*
Will the research involve the access, collection, use,
maintenance, or disclosure of protected health information (PHI)? PHI
is:
information about
a subject's past, present, or future physical or mental health, the
provision of healthcare to a subject, or payment for the provision of
healthcare to a subject; AND
maintained by a HIPAA-covered entity (e.g. healthcare provider, healthcare plan, or healthcare clearinghouse).
[Require Section 25]
[Require Section 25-1]
YesNo
07-1. Special Considerations - Continued
7-1.1* Will subjects receive payment or other incentives for their participation in the study? [Require Section 13]
YesNo
7-1.2*
Will subjects undergo healthcare-related treatments or procedures
(standard of care and/or research) as part of the study? [Require Section 14]
YesNo
7-1.3* Does this study involve the deception or concealment of subjects? [Require Section 27]
YesNo
7-1.4*
Excluding routine email correspondence, does this study involve the use
of the Internet or email as an integral part of the research design or
will sensitive information be transmitted by e-mail? [Require Section 28]
YesNo
7-1.5* Will the study collect data using surveys, interviews, or focus groups? [Require Section 29]
YesNo
7-1.6* Does this study require subjects to listen to an audio recording or view images? [Require Section 31]
YesNo
7-1.7* Will any drugs, biologics, radiopharmaceuticals, nutritional (e.g., herbal or alternative medication) supplements or other material be administered, implanted, or applied to the subjects as the object of the study? [Require Section 15]
YesNo
PLEASE NOTE: Since drugs are being used in this study, a MiChart order may need to be created; please allow sufficient time for the MiChart orderset to be created before starting your study.
7-1.8* Will the study involve a placebo (drug, device, procedure, intervention, surgery, etc.) control group? [Require Section 17]
YesNo
7-1.8.1* Is the placebo for a drug? [Require Section 15]
YesNo
7-1.9* Will the study involve human embryonic stem cells (hESCs) or induced pluripotent stem cells? [Require Section 19]
YesNo
7-1.10* Will the study have a Data and Safety Monitoring Plan (DSMP)? [Require Section 32]
YesNo
7-2. Special Consideration - Continued
7-2.1*
Will any devices be used, administered, implanted, or applied to the
subjects, or will human specimens be used to test in vitro diagnostic
devices? [IRBMED Applications Require Section 16]
YesNo
7-2.1.1*
Describe all devices that are the OBJECT of the study, or ARE RELEVANT
to the study. If this study is designed to test the safety or efficacy
of any of these devices, then this project is FDA-regulated and must be
reviewed by IRBMED.
We will use fMRI as a
way of collecting neural activation data of participants during software
engineering tasks. We are not evaluating the fMRI device itself.
The study will use the General Electric fMRI scanner (K091028) in the U-M functional MRI laboratory. The device has been assessed for safety and registered with the BEU.
7-2.2* Is the research testing or utilizing a health-related mobile software application that is:
Designed for a handheld (e.g., smartphone) or wearable mobile device (e.g., exercise tracking), or
Tailored to a mobile platform (i.e., a handheld commercial
or off-the-shelf computing platform, with or without wireless
connectivity) but executed (run) from a server
and the mobile software application/platform performs any of the following:
Uses a built-in feature of a device such as light, vibration, or camera to perform a medical device function.
Connects or links to an existing device to control its operation, function, or energy source.
Uses patient-specific data from a connected device
including a sensor or electrode to monitor, manipulate, calculate, or
analyze information.
Conveys diagnostic information, or provides education materials or encouragement.
Performs calculations, conversions, measurements or interpretations.
YesNo
Note: If there is intent to
introduce the mobile medical app into commercial distribution or to
publish via an app store (e.g., Google or Apple), you must contact the
Office of Technology Transfer at 734-763-0614 or um-software@umich.edu to discuss licensure and U-M branding.
7-2.2.1*
Is the mobile technology intended for use in performing a medical
device function (i.e. for diagnosis of disease or other conditions, or
the cure, mitigation, treatment, or prevention of disease)? If so, it is
a medical device, regardless of the platform on which it is run. [IRBMED Applications Require Section 16]
YesNo
7-2.2.2* Describe the health-related mobile software application and its intended use.
7-2.3* Will the subjects be exposed to any ionizing radiation during the course of this study? [Require Section 21]
YesNo
7-2.3.1* Will radiopharmaceuticals be administered to subjects as part of this study? [Require Section 15]
YesNo
7-2.4* Will any organs, tissues, or cells from humans (including fetal tissue) or animals be administered to the subjects for the purposes of this study? [Require Section 22]
YesNo
7-2.5* Does this study involve a gene transfer intervention or an intervention based on recombinant DNA technology? [Require Section 23]
YesNo
08. Subject Participation
8.1* Please indicate the number of subjects to be enrolled from ALL study locations to achieve the goal of the study:
30
8.2* Enter the estimated number of subjects to be enrolled at each University of Michigan site:
8.2* Enter the estimated number of subjects to be enrolled at each site:
8-1.1* At what point in the study are you planning on beginning the recruitment of subjects?
0-2 years after approval
8-1.2* Indicate which of the following established subject pools, if any, will be used for recruitment.
Select all that apply:
N/A
Provide Related UM IRB Project Number or Subject Pool Description:
8-1.3*
Describe the manner in which potential study subjects will be
recruited. List how, when, who will recruit and where they will
be recruited. Include any provisions to protect or maintain subject
privacy.
Participants
will be identified by their presence in various Computer science venues
(classes, labs, etc.). Graduate students, undergraduate students,
professors, and community members would all be considered eligible if
they demonstrate the required programming expertise for completing the
programming tasks. Other participants may learn of the study by word of
mouth from a study team member and may be eligible if they can
demonstrated the required expertise.
Subjects will be contacted
directly via email, letter, or presentation in group setting with
consent then obtained individually in a private setting. We will send
announcement emails to the departmental email lists to which
undergraduate majors are subscribed. We will not obtain a list of
individual email addresses.
We require participants with
programming and software engineering experience consistent with the
content taught in PI Weimer's course (Software engineering), and thus
will actively recruit in that class. Research Fellow Leach or
graduate student Huang will recruit once during the semester during a
class period (4:30pm in BBB 1607). To mitigate concerns of coercion, we
will take the following steps:
1) PI Weimer will not advertise
or be involved in the selection or recruitment of participants.
Instead, Research Fellow Leach or graduate student Huang will provide a
presentation (~2 minutes) advertising the study and offering Leach's
email address as a point of contact. Students interested in
participating will be encouraged to email Leach to establish an
appointment to meet for the fMRI study. 2) Students will not be given
extra credit, and students will have the option to participate after
final course grades have been submitted.
While we will need to
interact with participants via email for scheduling, we will not record
or retain their names or email addresses during this study. Rather, we
will keep the email address for scheduling purposes only, and delete
correspondence and addresses after the participant finishes the study.
8-1.3.1 If applicable, how will prospective subjects' healthcare providers (e.g., physician, dentist, etc.) be involved in the recruitment and/or be notified of their individual patients' participation in the study?
8-1.4* Explain how the recruitment strategy is equitable and represents the population required for the study. If the information is covered in the attached protocol, please indicate section.
Any
adult eligible for fMRI can participate in this study provided they
demonstrate the required programming expertise for completing the
programming tasks. Every candidate participant will be assessed for
minimal expertise using the same set of questions after receiving
informed consent. This minimal expertise is consistent with students
who have passed EECS280 and/or EECS281.
A number of MRI-safety
exclusion criteria are used in the blanket IRB and common throughout
MRI-related research. For safety purposes, we exclude candidates who
may have magnetic metal in their bodies (e.g., metal shavings from
metalworking).
Advertisements will be made broadly in relevant
classes as well as in public bulletin board spaces in relevant buildings
so as to reach the broadest eligible audience.
8-1.5*
Does the recruitment strategy involve contacting individuals
multiple times in an effort to secure their initial enrollment into
the study?
YesNo
8-1.5.1* Describe how frequently and in what manner individuals will be contacted. If the information is covered in the attached protocol, please indicate section.
8-1.6* Indicate which methods will be used for recruitment?
Check all that apply:
Face-to-face contact (e.g. during a health care visit or an interview at a home address, etc.)
Email
Public advertisement (e.g., bulletin boards, newspapers, radio, TV, websites, or on-hold telephone scripts, etc.)
If other please specify:
8-1.7 How will any email, address, and/or telephone lists be obtained?
CSE
departmental or class-specific email list will be used. These are
lists like cse-ugrads@umich.edu, which is an address that broadcasts
announcements to all subscribed individuals. We plan to use an email
list to which the undergraduate CS majors are subscribed and email lists
associated with the undergraduate software engineering course.
8-1.8* What materials will be used for recruitment? The IRB must approve all recruitment materials.
See Help for important information regarding the requirements for recruitment materials
Check all that apply:
Pre-screening questions
Flyers
Oral scripts
Email messages
If other please specify:
If Web pages will be used, provide the Web
address (URL) for the location where the pages will be posted (also
upload the content of the pages below):
Upload recruitment materials here:
See Help for more information about working with documents (e.g. uploading, downloading, and editing).
The general adult population (aged 18 or older); or
A subgroup of the general population which does not specifically target:
Pregnant women and/or fetuses
Lactating women
Women of child-bearing potential
Prisoners
Cognitively impaired adults
College students
Economically or educationally disadvantaged persons
Patients of the study team
Employees, students or trainees of the study team
Family members of the study team
where the survey is the sole interaction with the subject and does not pose more than minimal risk?
YesNo
09-1. Subject Populations
9-1.1* Is the research designed to include or allow the following populations?
Select all that apply
Normal, healthy subjects
Adultsage 18 and older
Minors able to consentto
treatments or procedures involved in the research, under the applicable
law of the jurisdiction in which the research will be conducted (e.g.
emancipated minors or minors seeking treatment for certain conditions.)
Children and/or Viable Neonates(i.e.
persons who have not yet reached the legal age for consent to
treatments or procedures involved in the research, under the applicable
law of the jurisdiction in which the research will be conducted)
[Require Sections 33 and 41]
Neonates of uncertain viability and/or nonviable neonates
(do not check this box if the research is solely retrospective. For
retrospective research regarding neonates of uncertain viability, check
the box for 'Children'. See Help for additional information.) [Require
Section 34]
Individuals and/or products involving human in vitro fertilization
Pregnant women and/or fetuses [Require Sections 35 and 41]
Lactating women [Require Section 36]
Women of child-bearing potential [Require Section 37]
Prisoners (If
the research includes a study population that is likely to become
incarcerated during the conduct of the research, also select this
category) [Require Section 38 and 41]
Cognitively impaired adults [Require Sections 39 and 41]
College students [Require Sections 40 and 41]
Economically or educationally disadvantaged persons [Require Section 41]
Patients of the study team [Require Section 41]
Employees, students or trainees of the study team [Require Section 41]
Family members of the study team [Require Section 41]
Unknown, unspecified population
10. Informed Consent - Adults
10.1* What type of informed consent will be obtained from adults or minors legally able to consent to treatments or procedures involved in the research?
With signature:
Comprehensive written
Written assent for cognitively or decisionally impaired adults
Without signature (waiver of documentation):
Comprehensive written
Comprehensive oral consent script
Assent for cognitively or decisionally impaired adults
Waivers of informed consent:
Request for waiver of informed
consent/parental permission/legally authorized representative consent
(Note: no longer required for screening/recruitment)
Request for waiver of assent for cognitively or decisionally impaired adults
Other:
Short form, comprehensive oral script, and witness
Request for alteration of informed consent requirements
Pre-existing consent(s) covers this activity
Re-consent/assent subjects for use of existing data/records/specimens for a new research purpose
10.1.2*
Describe the process to seek and obtain informed consent and/or assent
from adults. If requesting a waiver of documentation of assent, provide
justification here.
Upon receiving email
from interested participants, we will email the informed consent
documents back to them. We will not proceed with scheduling until
receiving informed consent. Subjects will also be given a written form
explaining all of the details of the experiment consistent with the fMRI
blanket IRB. Subjects will be given as much time as they require to
read, understand, and sign off on the informed consent form.
Additionally,
once the participant arrives for their scheduled scan, research Fellow
Kevin Leach and/or graduate student Yu Huang will sit with the subject
and explain the experiment, the process of the study, their rights,
risks, and benefits, and reaffirm their consent.
10.1.3* Is the cognitive capacity of the subjects expected to change significantly during the study?
YesNo
10.1.3.1*
Describe the plan to re-consent the subject or the subject’s legally
authorized representative after the change in the cognitive capacity of
the subject.
10-1.1*
All documents related to consent, assent, permission, and or debriefing
documents, including oral scripts must be uploaded here. If you are
requesting a waiver of documentation of informed consent, upload a copy
of any written materials to be provided to participants, and provide a
written description of any information to be provided orally.
10-1.1*
All template documents related to consent, assent, permission, and or
debriefing documents, including oral scripts must be uploaded here. If
you are requesting a waiver of documentation of informed consent, upload
a copy of any written materials to be provided to participants, and
provide a written description of any information to be provided orally.
10-1.1.1*
Does the Informed Consent use the sentences required for Applicable
Clinical Trials: "A description of this clinical trial will be available
on www.ClinicalTrials.gov, as required by US law. This website will not
include information that can identify you. At most, the website will
include a summary of the results. You can search this website at any
time."?
YesNo
10-1.2* Will the subjects be audiotaped, videotaped, or photographed (identifiable images of subject) during the research?
11.2* Explain how the subjects' privacy will be protected.
Participants are
interviewed in private before the fMRI scan. We do not collect personal
information from them as part of the research data, except for an audio
recording of their post questionnaire. We assess their C language
competency using a short written test and ask about their expertise
based upon years of experience programming.
Participants will
be assigned unique numbers. Physiological data collected from the fMRI
and survey data will be stored along with the unique number. fMRI
anatomical data will be de-identified to prevent facial reconstruction
in the event of a data breach. Moreover, their audio recording will
be transcribed to plain text, and their audio recording will be deleted.
Amendment 85172:
We
will audio-record the participant's post-questionnaire. This audio
file will be stored on an encrypted volume separate from the other
research data collected about each participant, organized by participant
ID number. Huang, Leach, or Krueger will transcribe the audio within
30 days of the participant's post-questionnaire, at which point we will
delete the original audio file. The paragraphs above reflect this
addition.
11.3* How
will the study team protect research records, data, and/or specimens
against inappropriate use or disclosure, or malicious or accidental loss
or destruction in order to protect the confidentiality of subject data?
Select all that apply:
Locked office
Locked cabinet or storage unit
Restricted access
Secure laptop
Individual ID plus password protection
Encryption of digital data
Network restrictions
Security software (firewall, anti-virus,
anti-intrusion) is installed and regularly updated on all servers,
workstations, laptops, and other devices used in the project
Safe disposition/destruction of data or devices, as
appropriate (e.g., shredding paper documents, destroying disks or thumb
drives, secure erasure of electronic media)
If other please specify:
11.4* Does either statement apply to this research:
Research has NIH,
CDC, or FDA funding, or other federal funding from an agency that
automatically issues a Certificate of Confidentiality as part of the
terms of the award:
The study will include identifiable sensitive information,
identifiable biospecimens, individual human-level genomic
data/biospecimens, or any information about an individual for which
there is at least a very small risk, as determined by current scientific
practices or statistical methods, that some combination of the
information, a request for the information, and other available data
sources could be used to deduce the identity of an individual.
or
Research does NOT have NIH, CDC, or FDA funding, or
other federal funding from an agency that automatically issues a
Certificate of Confidentiality as part of the terms of the award:
The study will include identifiable, sensitive information
or identifiable biospecimens that, if revealed, might place the subjects
at risk for personal safety, criminal or civil liability, or damage to
their financial standing, employability, insurability, or reputation.
[Require Section 11-2]
YesNo
11.5* Will data be provided to a repository as part of a data sharing agreement?
YesNo
11.5.1* Please indicate the repository:
Select all that apply:
There are no items to display
If Other, please specify:
11.6* What will happen to the data and/or any specimens at the conclusion of this study?
Select all that apply:
Retain for future research use - requires Section 11-4
11.6.1*
If the data and/or specimens will be destroyed, describe the specific
plan that will be employed following the required retention period.
11.6.2*
If the data and/or specimens will be retained for study
recordkeeping purposes, provide the following information (if
covered in the attached protocol, please indicate section):
expected duration of the retention period,
any changes in the conditions or arrangements for storage
of research data/specimens during the retention period, if different
from those listed above in question 11.3.
11-3. End of Subject Participation
11-3.1* What specific criteria will be used to prematurely end a particular subject's participation in the study (If covered in attached protocol or informed consent, indicate specific location).
The
participants will complete a skills-based questionnaire before entering
the MRI machine in person with pen and paper. The questionnaire will
be graded quickly. If they do not answer all of the questions
correctly, they will receive some compensation ($25) and their
participation will end at that point.
We will ask participants
after their trial ends how they prefer to be compensated (whether they
complete the fMRI trial, are removed for inability to complete the test,
or decide to withdraw). We will collect the relevant information to
submit to HSIP for remuneration.
The participants will be shown
the operation of the MRI, and will be given the opportunity to
experience going into the tube once before beginning the actual study.
Participants will be instructed that they can leave the study at any
time for any reason. The fMRI is equipped with a 'panic' button. The
subject will be instructed to use the button for any reason if they
decide they no longer want to participate.
11-3.2*
If a participant withdraws from the research, what is the plan to use,
disclose, store, or destroy the participant's data and/or specimen?
Destroy any electronic data related to the participant securely, and destroy copies of the survey used to filter participants.
11-4. Retention of Data and/or Specimens Detail
Retention may be for future research by the investigator and/or the creation of a bank or repository.
Completion of this section is required based on the response provided to question 11.6.
11-4.1* What is the intent or purpose of retaining the data and/or specimens?
For
follow up work and dissemination to the academic community. This
domain of research is largely unexplored and related data is difficult
to obtain. The academic community would benefit greatly from having
(anonymized) data available for comparison in subsequent studies.
11-4.2* Where will you store the data and/or specimens?
Only at the University of Michigan
If Other Institutions, please specify:
11-4.3* Describe the arrangements for the storage conditions, management, and security of the data and/or specimens. Include the following as applicable:
Personnel access to data and/or specimens
Whether identifiers will be removed and the key to any code destroyed
For coded data and/or specimens, indicate who holds key to
the code and where it is stored in relation to the data and/or specimens
Storage plan
Plan to protect privacy in transfer to other collaborators.
PI
Weimer has secure office space allocated in the Beyster building for
storing sensitive information. Only PI Weimer and Research Fellow Leach
will have key access to the office.
We collect identifiers
necessary to reimburse the participants via HSIP. However, these
identifiers will be deleted once the participant has received their
reimbursement. We collect audio recordings of the participant's post
questionnaire; other identifiers are not stored or collected as part of
the research data. Research data will be stored on encrypted volumes
secured by a passphrase that will be shared between PI Weimer, Research
Fellow Leach, and UCSB collaborator Tyler.
All data will be
de-identified to protect participant confidentiality. This includes
de-identifying the anatomical brain information obtained from the MRI
and transcribing the audio recording to plain text.
13. Subject Payments Or Other Incentives
Completion of this section is required based on the response provided to question 7-1.1 or 7-3.3.
13.1* Indicate all payments or other incentives provided to subjects for their participation in this study:
Select all that apply:
Cash
Check
Payment Voucher
If other, please specify:
13.2*
If the subject is a child (under the age of majority), are any of the
payments or incentives intended for the parent/guardian of the child?
N/A
13.3*
Estimate the maximum total payment (including cash, checks, gift cards,
and other cash-equivalent incentives) that an individual subject could
receive for participating in this research in a single calendar year.
13.3.1*
Please indicate what information you will be collecting from subjects
in order to distribute their incentive or compensation.
Select all that apply:
Name
Address
Email
13.4*
Describe the frequency of the payments or incentives. If applicable,
list any healthcare procedure(s) that will be provided to subjects at no
charge.
One
payment will be issued within a month of the conclusion of the study.
If a participant is found ineligible during the fMRI safety screening or
skills assessment, they will receive $25.
The payment will be
given based upon the participant's preference. We will collect the
participant's name, address, and email address so that HSIP can
compensate them as appropriate.
13.5* What is the justification for offering these payments or incentives?
The
study will take approximately 1.5 hours of the participants' time.
Additionally, participants are required to have a minimal expertise with
computer science. We want to compensate participants for their time at
a reasonable rate (i.e., $50/hr for a typical software developer).
13.6* What is the plan to compensate subjects withdrawing from the research prior to completing the entire study.
Participants
will still receive compensation even if they decide to withdraw. If
they withdraw during the study, they will receive $75. If they are
excluded based on the skills assessment or fMRI safety screening, they
will receive $25.
29. Survey Research
Completion of this section is required based on the response provided to question 7-1.5.
29.1* Provide a list of all surveys and interviews used in the study:
29.13* Will the research involve the use of focus groups?
YesNo
29.13.1* How will the identity of individuals participating in the groups be protected?
29.14* Is any of the material disturbing?
YesNo
29.15*
Describe the arrangements made to provide professional counseling or
support resources to any subjects desiring such assistance as a result
of their participation in the study.
29.16* Indicate how the list of counseling or support resources will be provided:
If other, please specify:
Survey Detail
29.2* Survey or interview name:
Austism Spectrum Quotient
29.3* Is the design or development of this survey instrument dependent on receipt of funding or hiring of personnel?
YesNo
29.4* In what manner will the survey or interview be conducted (e.g., in-person, Internet, mail, telephone, etc.)? Special
Note: For electronic surveys, the eResearch ID number must be included
in the informed consent document (uploaded in section 10-1) or other
material that serves as the informed consent.
This survey will be emailed to the participant before their scheduled fMRI scan.
29.5* What is the predicted response rate?
100 %
29.6* What is the total number of questions?
50
29.7* What is the anticipated cumulative amount of time required for each subject?
10 minutes
29.8* What is the total number of interviews/data collection interactions with an individual subject?
1
29.9* Does the survey or interview contain questions of a sensitive nature (e.g., mental illness, sexual abuse, illicit drug use, etc.)?
YesNo
29.10* Is the survey or interview likely to produce psychological discomfort or negative feelings in the subjects?
YesNo
29.11* Has the survey instrument been validated or used in standard practice?
YesNo
29.11.1* If yes, describe the origin of the instrument.
Cohen
et al. The Autism-Spectrum Quotient (AQ): Evidence from Asperger
Syndrome/High-Functioning Autism, Males and Females, Scientists and
Mathematicians. Journal of Autism and Developmental Disorders, Vol. 31,
No. 1, 2001
29.3* Is the design or development of this survey instrument dependent on receipt of funding or hiring of personnel?
YesNo
29.4* In what manner will the survey or interview be conducted (e.g., in-person, Internet, mail, telephone, etc.)? Special
Note: For electronic surveys, the eResearch ID number must be included
in the informed consent document (uploaded in section 10-1) or other
material that serves as the informed consent.
Before entering the fMRI to complete the study, participants will be asked to complete a form with questions on it in-person.
29.5* What is the predicted response rate?
100 %
29.6* What is the total number of questions?
6
29.7* What is the anticipated cumulative amount of time required for each subject?
5-10 minutes
29.8* What is the total number of interviews/data collection interactions with an individual subject?
2
29.9* Does the survey or interview contain questions of a sensitive nature (e.g., mental illness, sexual abuse, illicit drug use, etc.)?
YesNo
29.10* Is the survey or interview likely to produce psychological discomfort or negative feelings in the subjects?
YesNo
29.11* Has the survey instrument been validated or used in standard practice?
YesNo
29.11.1* If yes, describe the origin of the instrument.
This questionnaire was used in previously peer-reviewed, IRB-approved research.
29.3* Is the design or development of this survey instrument dependent on receipt of funding or hiring of personnel?
YesNo
29.4* In what manner will the survey or interview be conducted (e.g., in-person, Internet, mail, telephone, etc.)? Special
Note: For electronic surveys, the eResearch ID number must be included
in the informed consent document (uploaded in section 10-1) or other
material that serves as the informed consent.
This survey will be emailed to the participant before their scheduled fMRI scan
29.5* What is the predicted response rate?
100 %
29.6* What is the total number of questions?
18
29.7* What is the anticipated cumulative amount of time required for each subject?
5 minutes
29.8* What is the total number of interviews/data collection interactions with an individual subject?
1
29.9* Does the survey or interview contain questions of a sensitive nature (e.g., mental illness, sexual abuse, illicit drug use, etc.)?
YesNo
29.10* Is the survey or interview likely to produce psychological discomfort or negative feelings in the subjects?
YesNo
29.11* Has the survey instrument been validated or used in standard practice?
YesNo
29.11.1* If yes, describe the origin of the instrument.
29.3* Is the design or development of this survey instrument dependent on receipt of funding or hiring of personnel?
YesNo
29.4* In what manner will the survey or interview be conducted (e.g., in-person, Internet, mail, telephone, etc.)? Special
Note: For electronic surveys, the eResearch ID number must be included
in the informed consent document (uploaded in section 10-1) or other
material that serves as the informed consent.
This survey will be given to the participant in person after completing the post questionnaire.
29.5* What is the predicted response rate?
100 %
29.6* What is the total number of questions?
20
29.7* What is the anticipated cumulative amount of time required for each subject?
10 minutes
29.8* What is the total number of interviews/data collection interactions with an individual subject?
1
29.9* Does the survey or interview contain questions of a sensitive nature (e.g., mental illness, sexual abuse, illicit drug use, etc.)?
YesNo
29.10* Is the survey or interview likely to produce psychological discomfort or negative feelings in the subjects?
YesNo
29.11* Has the survey instrument been validated or used in standard practice?
YesNo
29.11.1* If yes, describe the origin of the instrument.
Vz-2-BRACE scoring instrument for spatial ability.
29.3* Is the design or development of this survey instrument dependent on receipt of funding or hiring of personnel?
YesNo
29.4* In what manner will the survey or interview be conducted (e.g., in-person, Internet, mail, telephone, etc.)? Special
Note: For electronic surveys, the eResearch ID number must be included
in the informed consent document (uploaded in section 10-1) or other
material that serves as the informed consent.
This survey will be emailed to the participant before their scheduled fMRI scan.
29.5* What is the predicted response rate?
100 %
29.6* What is the total number of questions?
60
29.7* What is the anticipated cumulative amount of time required for each subject?
10 minutes
29.8* What is the total number of interviews/data collection interactions with an individual subject?
1
29.9* Does the survey or interview contain questions of a sensitive nature (e.g., mental illness, sexual abuse, illicit drug use, etc.)?
YesNo
29.10* Is the survey or interview likely to produce psychological discomfort or negative feelings in the subjects?
YesNo
29.11* Has the survey instrument been validated or used in standard practice?
YesNo
29.11.1* If yes, describe the origin of the instrument.
29.3* Is the design or development of this survey instrument dependent on receipt of funding or hiring of personnel?
YesNo
29.4* In what manner will the survey or interview be conducted (e.g., in-person, Internet, mail, telephone, etc.)? Special
Note: For electronic surveys, the eResearch ID number must be included
in the informed consent document (uploaded in section 10-1) or other
material that serves as the informed consent.
in-person,
after successful completion of the fMRI trial, we will sit with the
participant and ask them each question based upon responses provided to a
random subset of tasks they were given during the fMRI.
29.5* What is the predicted response rate?
100 %
29.6* What is the total number of questions?
3
29.7* What is the anticipated cumulative amount of time required for each subject?
5-10 minutes
29.8* What is the total number of interviews/data collection interactions with an individual subject?
1
29.9* Does the survey or interview contain questions of a sensitive nature (e.g., mental illness, sexual abuse, illicit drug use, etc.)?
YesNo
29.10* Is the survey or interview likely to produce psychological discomfort or negative feelings in the subjects?
YesNo
29.11* Has the survey instrument been validated or used in standard practice?
YesNo
29.11.1* If yes, describe the origin of the instrument.
29.3* Is the design or development of this survey instrument dependent on receipt of funding or hiring of personnel?
YesNo
29.4* In what manner will the survey or interview be conducted (e.g., in-person, Internet, mail, telephone, etc.)? Special
Note: For electronic surveys, the eResearch ID number must be included
in the informed consent document (uploaded in section 10-1) or other
material that serves as the informed consent.
This survey will be emailed to the participant before their scheduled fMRI scan.
29.5* What is the predicted response rate?
100 %
29.6* What is the total number of questions?
6
29.7* What is the anticipated cumulative amount of time required for each subject?
5 minutes
29.8* What is the total number of interviews/data collection interactions with an individual subject?
1
29.9* Does the survey or interview contain questions of a sensitive nature (e.g., mental illness, sexual abuse, illicit drug use, etc.)?
YesNo
29.10* Is the survey or interview likely to produce psychological discomfort or negative feelings in the subjects?
YesNo
29.11* Has the survey instrument been validated or used in standard practice?
YesNo
29.11.1* If yes, describe the origin of the instrument.
This survey has been used in IRB-approved studies at UCSB's Psychology department.
Check here to indicate that the material is not available electronically.
31.2* Are any of the materials likely to produce psychological discomfort or negative feelings in the subjects?
YesNo
31.2.1*
Describe the arrangements made to provide professional counseling or
support resources to any subjects desiring such assistance following
their participation in the study.
31.2.2* Indicate how the list of counseling or support resources will be provided:
If other, please specify:
32. Data Safety And Monitoring Plan
Completion of this section is required based on the response provided to question 7-1.10.
The
principal investigator (PI) has the ultimate responsibility for the
conduct of this research study. The study-specific scientific protocol
should include detailed information about tests and procedures employed
to safeguard the health and safety of the subjects. Additionally, the PI
must prepare a specific data and safety monitoring plan taking into
account national guidelines and the study's complexity, risk, and size.
The plan should include the administrative processes for recording and
evaluating the data quality and integrity. The plan should also specify
the responsibilities of research team members and the schedules for
reviewing and reporting study progress and adverse events.
Components
of this plan relating to the protection of subject privacy and data
confidentiality should already have been included in the
Confidentiality/Security section of this application.
Additionally,
certain members of the research team must complete the PEERRS mandatory
training on human subject protection. This includes personnel joining
the study team after the initiation of the study.
The Risk Level has been indicated as:
Name
Risk Level
Direct Benefit
HUM00138634
No more than minimal risk
no
32.1*
Indicate who will provide study information and instructions to the
subjects beyond what is included in the informed consent document.
Select all that apply:
Co-I
If other, please specify:
32.2* Indicate who will obtain informed consent from the subjects.
Select all that apply:
Co-I
If other, please specify:
32.3* Indicate what mechanism(s) will be used for monitoring subjects and identifying adverse events.
Mechanism (Select at least one:)
Conducted by:
Direct interviews/ physical exams conducted by:
Select all that apply:
Co-I
Review of lab work, tests, procedures, etc. by:
Select all that apply:
PI
Co-I
Telephone follow-up conducted by:
Select all that apply:
There are no items to display
Self-reporting by subject
Instructions must be included in the Informed Consent Document.
Other
Reminder: Adverse Events that come to the attention
of any member of the study team must be reported to the PI in a timely
manner.
32-1. Data and Safety Monitoring Plan - AE Reporting
Adverse Event (AE) Reporting
32-1.1* Adverse events will be reported to:
Organization
Reporting Mechanism
IRB
eResearch AE/ORIO submission
DSMB/DSC/independent monitor
UMHS Cancer Center DSMB
Federal oversight agencies (FDA, RAC, etc)
Sponsor (federal, industry, private, etc)
Other
If other, please specify:
32-1.2* Indicate the AE reporting timetable that will be used to report adverse events to the IRB:
Standard IRBMED AE reporting timetable
32-1.2.1*
Indicate the reason for selecting the study-specific AE reporting
rather than the Standard IRBMED AE Reporting Timetable.
Select all that apply:
There are no items to display
If other, please specify:
32-1.2.2*
Provide the study-specific AE reporting plan. If the
study-specific AE reporting plan is included in the previously uploaded
scientific protocol, indicate section.
32-1.3* Affirm that the adverse events will be reported to the IRB according to the following generalized AE GRADING SCALE:
0 - No adverse event
1 - Mild AE – No treatment needed
2 - Moderate AE – Resolved with treatment
3 - Severe AE – Inability to carry on normal activities, required professional medical attention
4 - Life-threatening or disabling AE
5 - Fatal AE
32-1.4* Will Serious Adverse Events (SAEs) be categorized according to the following FDA definition?
N/A - not FDA-regulated
Death
A life-threatening adverse drug experience
Inpatient hospitalization or prolongation of existing hospitalization
A persistent or significant disability/incapacity
A congenital anomaly/birth defect
Important medical events that may not result in death, be
life-threatening, or require hospitalization may be considered a serious
adverse drug experience when, based upon appropriate medical judgment,
they may jeopardize the patient or subject and may require medical or
surgical intervention to prevent one of the outcomes listed in this
definition. Examples of such medical events include allergic
bronchospasm requiring intensive treatment in an emergency room or at
home, blood dyscrasias or convulsions that do not result in inpatient
hospitalization, or the development of drug dependency or drug abuse.
32-1.5*
Affirm that either the principal investigator or a co-investigator will
determine the ATTRIBUTION/RELATEDNESS for each adverse event.
Definitely related
Probably related
Possibly related
Unlikely to be related
Definitely not related
32-1.6* Affirm that the EXPECTEDNESS will be assigned for each adverse event according to the following definitions:
Unexpected adverse events (i.e., has NOT been addressed or described
in one or more of the following: Informed consent document(s) for this
study, IRB application for this study, grant application or study
agreement, protocol or procedures for this study, investigators'
brochure or equivalent (for FDA regulated drugs or devices), DSMB/DSC
Reports, published literature, other documentation)
Expected adverse events (i.e., has been addressed or described
in one or more of the following: Informed consent document(s) for this
study, IRB application for this study, grant application or study
agreement, protocol or procedures for this study, investigators'
brochure or equivalent (for FDA regulated drugs or devices), DSMB/DSC
Reports, published literature, other documentation, or characteristics
of the study population)
32-2. Data Safety and Monitoring Plan - Monitoring the Study
Monitoring the Study
32-2.1*
Indicate the frequency with which the study team will conduct scheduled
assessments of study recruitment, data integrity and quality, adverse
events, withdrawals, and compliance with protocol plan.
Monthly
If other, please specify:
32-2.1.1* If quarterly or other, provide a justification for the assessment schedule.
32-2.2* Study
oversight and safety monitoring may be required based on the
nature, size, and complexity of the study. Indicate the
responsible entities.
Select all that apply:
No additional monitoring is required – the
nature, size, and complexity of this study does not require additional
safety monitoring to that provided by the IRB.
Independent monitor
Internal committee
Sponsor
Data and Safety Monitoring Board (DSMB) or Data Safety Committee (DSC)
UMHS Cancer Center DSMB
Other
If other, please specify:
If no additional monitoring is required, jump to 32-2.3.
32-2.2.1 Provide the names and areas of expertise of those providing this additional monitoring
32-2.2.2 Indicate the frequency with which the additional monitoring activities will be conducted.
If other, please specify:
32-2.2.3 Indicate the data that will be reviewed.
Select all that apply:
There are no items to display
32-2.2.4 If a DSMB or DSC charter exists, upload it here.
Completion of this section is required based on the response provided to question 9-1.1.
37.1*
Is there a potential that any of the study procedures pose significant
physical or psychological risks to women who are or may be pregnant, or
to a fetus?
YesNo
37.1.1* List the study procedures that may pose risks to pregnant women or fetuses.
MRI excludes pregnant women from participating.
37.1.2*
Describe the steps that will be taken prior to the conduct of these
procedures to confirm that subjects are not pregnant.
As
part of the safety screening for the MRI, participants are asked if
they are pregnant. The fMRI laboratory provides a free urine-based
pregnancy test for women who are unsure whether they are pregnant.
Women who indicate or test that they are pregnant will be excluded.
37.1.3*
Describe the measures that will be required to prevent pregnancy during
or, if applicable, following subjects' exposure to the study
procedures. Specify the duration of the preventative measures.
The
fMRI laboratory provides a free urine-based pregnancy test for women
who are unsure whether they are pregnant. Women who indicate or test
that they are pregnant will be excluded.
41. Subjects Vulnerable to Coercion
Completion of this section is required based on the response provided to question 9-1.1 or 9-2.1.
The following subject populations, vulnerable to coercion or undue influence, have been identified for inclusion in the study.
College Students
41.1* What is the justification for the inclusion of these subject populations?
We require participants
who are relatively competent programmers. Additionally, we require
participants that have a certain level of felicity with core software
engineering concepts (e.g., C programming, version control, code
review). PI Weimer's undergraduate software engineering course covers
relevant material and thus provides a population of
appropriately-skilled students.
41.2*
Describe the additional safeguards that have been included in this
study to protect the rights and welfare of these subjects.
Students will not be
recruited by PI Weimer. Students will not receive extra credit and
their course grade will not be influenced by their participation in the
study. All anatomical data will be de-identified before analysis.
While we will collect audio recordings of participants' post
questionnaire, we will transcribe these audio files to plaintext.
Further, we will not retain other personally identifiable information
after each participant receives their compensation.
44. Additional Supporting Documents
44.1 Please upload any additional
supporting documents related to your study that have not already been
uploaded. Examples include, but are not limited to, data collection
sheets, newsletters, subject brochures, and instructional brochures.
44.2 Enter any information that should
show in a “Supporting Documents” list on the current submission’s
approval notice, such as document names and version numbers or version
dates. Text entered here will AUTOMATICALLY appear word-for-word on the
approval letter.
45. End of Application
The form
was successfully submitted. Click 'Exit' or 'Finish' to leave the
form.